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Abstract
Vascular Dementia (VaD) is an important public health concern, which causes significant
morbidity and mortality amongst populations around the world. With the increases in average age
of individuals and prevalence of cardiovascular risk factors, the incidence of vascular cognitive
impairment (VCI) and VaD are on the rise. Most of this increase will come from cerebral small
vessel disease (CSVD) as treatment for large vessel disease improves. Yet, very few interventions
are recommended for CSVD beyond control of risk factors.
In this thesis, we propose a non-pharmacological intervention, which we believe may
address executive dysfunction in VCI due to CSVD. CSVD impairs functional frontal-subcortical
connectivity and results in cognitive and functional impairments. Given the plasticity in these
circuits, despite old age, cognitive training may be a good candidate for improving cognition in
CSVD. However, previous studies have suffered from heterogeneity of pathologies in VCI by
including both large and small vessel disease. Furthermore, they have often not considered the
effects of anxiety and depression, which we aim to exclude from the study. Finally, these studies
do not use validated composite scores as a primary endpoint and currently do not use any
biomarkers to follow the progress of subjects. In this study, we aim to partially address these
shortcomings and offer a more rigorous approach to cognitive training.
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Chapter 1 – Introduction
1.1 Background: Vascular Dementia
1.2 Vascular Dementia: Large vessel vs. small vessel disease
Vascular dementia (VaD) is a widely recognized public health concern which imposes
significant clinical, social, and financial burdens on society. Vascular dementia is the second most
common form of dementia after Alzheimer’s Disease (AD). Its prevalence in the United States is
reported to be 8-10%,1 but this is likely to be an underestimation given that most cases of mixed
vascular and Alzheimer’s pathology are reported as AD.2 Currently, research into VaD is in its
infancy with definitive diagnostic criteria and biomarkers still in development. Research into VaD
is a critical and urgent area of medical research since VaD is shown to lower median life
expectancy, create greater health care expenditures, and have higher rates of comorbidity when
compared to AD.1
VaD is the result of vascular brain injury from large vessel strokes or cerebral small vessel
disease (CSVD). There are important distinctions between these two categories as they are distinct
diseases and require different approaches: Large vessel disease is caused by lesions in the setting
of a large vessel becoming occluded. All large vessels and their tributaries may suffer from strokes
including branches of the carotids, anterior, middle, and posterior cerebral arteries. Occlusion may
occur due to cardioembolic, arterioembolic, or atherosclerotic etiologies. Large vessel strokes can
affect cognition proportionate to the extent of damage they cause to the brain. In contrast, “strategic
infarcts” can cause severe cognitive deficits by anatomically limited lesions when they affect highly
connected areas of the brain networks. These include the anterior and median thalamus, medial
temporal lobes, basal ganglia, angular gyrus, and the fornices.3 Treatment strategies for strokes are
well established. In the acute setting, thrombolysis and endovascular interventions may be
considered, to reverse vessel occlusion. In the immediate post-stroke period, stroke rehabilitation
aims to mitigate functional impairments in speech, vision, strength, coordination, or balance.4
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Multidisciplinary interventions are commonly implemented, and include exercise, cognitive
training, and learning compensatory strategies.4 There is evidence that constraint-induced
movement therapy, mental practice, mirror therapy, and high doses of repetitive exercises are
effective in regaining motor function.5
Cerebral small vessel disease is patho-physiologically distinct from large vessel disease.
CSVD was originally thought to be an accumulation of small strokes,6 however this paradigm has
been abandoned as large vessel disease treatments proved to be ineffective in CSVD. 7 We have
learned that CSVD is a heterogenous disease that can damage the cerebral vasculature by different
pathological processes. Different pathologies may be at play in CSVD. These pathologies are
sorted into six broad categories based on their etiology in the Pantoni classification system which
includes arteriosclerosis, cerebral amyloid angiopathy, hereditary angiopathies, inflammatory
angiopathy, venous collagenosis and others.8
In this project, we will confine our interest to CSVD caused by arteriosclerosis, cerebral
angiopathy, and micro embolism. These represent the increasingly common “white matter disease”
seen in memory clinics. Stroke rehabilitation is well characterized and established. The role of
non-pharmacological intervention in CSVD is less well established and may represent a major new
way in which CSVD is managed.
Several lesions related to CSVD appear to contribute to the pathophysiology of cognitive
disorders. One category is that of lacunar infarcts. Lacunar infarcts are small, non-cortical infarcts,
of about 0.3 mm to 15 mm in size, that result from a small, single penetrating branch from a large
cerebral artery becoming occluded.9 These occluded branches tend to be acutely angled and stem
from the Circle of Willis, causing lacunar infarcts to have a predilection for the basal ganglia,
subcortical white matter, and the pons.10 Lacunar infarcts are reported to account for 15% to 26%
of ischemic strokes.11 These lacunar infarcts preferentially affect the cortico-subcortical circuitry
passing though the basal ganglia and the thalamus.
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Other pathologies include cerebral amyloid angiopathy, which is caused by the deposition
of amyloid in small vessels. For most part, this causes occlusion of small vessels especially in the
partieto-occipital white matter.12 It also increases the risk of microhemorrhages seen preferentially
in the posterior fossa.12 Enlarged perivascular spaces are another marker of vascular disease.
Finally white matter hyperintensities represent various vascular related pathologies.8

1.3 Current therapeutic approaches to CSVD
Presently there are no interventions for cognitive impairment caused by CSVD which are
strongly rooted in evidence. Short of a disease modifying strategy, approach to the cognitive effects
of CSVD probably fall into the following categories:
-

-

-

Secondary prevention measures addressing vascular pathology:
o

Pharmacological: For example, there is good evidence that strict blood pressure
control may slow the progression of CSVD and its cognitive consequences.13 The
evidence for other vascular risk factors is less strong.

o

Exercise and diet: Aerobic-based exercise in the acute period improved memory
moderately, but long-term exercise, defined as 14 months, did not.14 Aerobic
intervention however has been associated with stimulating the release of factors
that promote dynamic network connectivity and neuro-vasculature protection, like
brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and
insulin-like growth factor (IGF-1).15

Interventions to improve cognition:
o

Pharmacological: there is evidence that cholinesterase inhibitors have a modest
effect on cognition in CSVD.16,17

o

Non-pharmacological: Cognitive training was shown in one study to improve
cognitive function up to five years post-training in the elderly with healthy
cognitive functions.18 A Cochrane review found it to have only small beneficial
effects in people with mild-to-moderate AD and VaD for cognitive rehabilitation
and not cognitive training, but the quality of the studies were graded as low-tomoderate.19 In the Cochrane review on Attention Process Training, small benefits
were found in performing activities of daily living.20 Studies also found a relative
association between attentional processes and behavioral outcomes. 21

Treatment of neuropsychiatric comorbidities: Improvements in depression and anxiety will
prevent against cognitive decline because psychiatric diseases can increase one’s risk for
dementia.22,23

8

1.4 The Science Underlying our Proposed Experiment
1.5 Network disruption in CSVD
CSVD affects white matter preferentially, and as such, can be seen in terms of changing
connectivity in the brain.

CSVD has a predilection for interruption of frontal-subcortical

circuitry.24 Frontal-subcortical impairment is characterized by prominent deficits in executive
functioning, mentation speed, memory retrieval, attention25, as well as gait apraxia26, bladder
dysfunction, pseudobulbar affect, apathy27, and depression28. 24
Classically the frontal-subcortical circuitry are divided into five sub-circuits, three of which
seem particularly vulnerable to CSVD: the dorsolateral prefrontal circuit, anterior cingulate circuit,
and the orbitofrontal circuit. 29 These circuits send afferent projections to the thalamic nuclei, basal
ganglia, or amygdalate nuclei, and send efferent projections to the inferotemporal, posterior
parietal, or pre-striate cortices.29 Collectively, disruptions to these circuits have persistently
presented with deficits in executive functions, apathy, and impulsivity.29
More specifically, disruptions to these individual circuitries, or functional networks, will
present with specific-behavioral deficits. Dorsolateral prefrontal dysconnectivity is associated with
poor behavioral responses because it can no longer organize the information that is integrated into
task-related actions.29 Anterior cingulate dysconnectivity is associated with poor motivational
behavior.29 Orbitofrontal circuit dysconnectivity is associated with emotional dysregulation
because it integrates limbic and emotional information into behavioral responses.29
Given that CSVD causes disruption of brain’s neural networks, one approach to improving
task-specific performance may be adaptive changes, both functional and structural, to the network.
Brain’s ability to change itself adaptively in response to experience is called neuroplasticity.
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1.6 Neuroplasticity
The definition of neuroplasticity is varied and evolving. Neuroplasticity refers to adaptive
changes in brain connectivity and structures in response to experience. The oldest conception of
plasticity belongs to Donald Hebb who discovered that concurrent activation of both pre- and postsynaptic neurons causes strengthening of synaptic connection. This is sometimes expressed as
“neurons that fire together, they wire together.”30 More broadly, neuroplasticity may involve
changes in synaptic strength or neuronal excitability. These can occur due to changes in the
probability of neurotransmitter release and/or changes in receptor density.31 In the short term,
plasticity is protein synthesis independent.31 In the long term, there are transcriptional changes
which can target individual dendritic spines.31 Dendritic spines are highly dynamic: they are
created and either grow, shrink or disappear.31 Dendritic spine turnover increases during
adolescence, stimulation and exercise.31 Often-used dendritic spines consolidate, while rarely used
connections are pruned.31 These, along with mechanisms that change synaptic strength and
neuronal excitability, represent important mechanisms by which the brain learns and compensates
for damage. Experience-induced neuroplasticity may be useful in ‘rewiring” damaged networks.31
The properties of experience-induced neuroplasticity were summarized by Kleim and
Jones.32 Here we paraphrase and summarize their list as follows:
-

General premise:32
o
o

-

Dosing: plasticity occurs for skillful tasks performed at: 32
o
o
o

-

Synaptic density and neuronal excitability decrease with disuse of brain function
and increase with use.
Changes that occur within used and unused networks are specific for brain
function.

High repetition
High intensity
Sufficient duration of time

Optimization: Plasticity is most effective: 32
o
o

In particular windows of time, including brain damage
For high salience tasks
10

o
-

In younger subjects

Interaction with other domains:32
o
o

Transference: the property that training for one brain function will improve
similar brain functions using similar anatomical structures.
Interference: that improvement in one brain function may be detrimental to the
performance of another function.

One particular form of plastic changes in neuronal excitability relates to the connections in
layer III of the prefrontal cortex.33 Arnsten and others have worked extensively on this
phenomenon, which they have termed Dynamic Network Plasticity.33 The basic premise is that high
levels of norepinephrine cause reduced neuronal excitability, and in essence, will cause reduction
in functional connectivity.33,34 This is significant for our purposes because fluctuations in anxiety
from day-to-day may confound any measurement of connectivity in subjects. We will now turn
our attention to the techniques which we hope to employ in this experiment.
1.7 Intervention 1: Dual N-Back
Dual N-Back is one of the most studied types of adaptive brain training. It is a game in
which participants are presented with two series of stimuli, and the task is to decide whether the
current stimulus matches with the one presented n-items back. The goal is to increase taskdifficulty level, which is adjusted to one’s performance. In the Dual N-Back model, the ability to
manipulate two tasks simultaneously is possible because of working memory and the coordinated
interactions between the prefrontal cortex (PFC) and the basal ganglia (BG).35
Increase in task-difficulty is an important feature of Dual N-Back because of its
associations with greater learning and structural change. Cognitive loading involves modulation
and recruitment of additional networks when completing complex tasks or when other networks
have become compromised.36-39 Cortical areas recruited by Dual N-Back include the
lateral premotor cortex; dorsal cingulate and medial premotor cortexes; dorsolateral and
ventrolateral prefrontal cortexes; frontal poles; medial and lateral posterior parietal cortexes and
parietal lobe; and, the anterior corpus collosum.40
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Involvement of frontoparietal, striatal, and thalamic regions support the possibility of
cognitive transfer gains to other cognitive domains.41 This is supported by improvements in
attention42,43, reasoning, and the ability to solve novel problems (“fluid intelligence”) after playing
Dual N-Back.44 Executive functioning is believed to be dependent on working memory, attention,
and episodic memory retrieval,45 which are cognitive domains that have been strengthened by Dual
N-Back.42,44,46 Executive functioning is also likely to improve more directly since Dual N-Back
strengthens the frontoparietal network.47
Adaptive cognitive trainings have shown only modest improvements in cognition of the
elderly with mild cognitive impairment (MCI) and dementia.19 The small effect size may be due
to one of the following:
1) Incorrect experimental design: problems with placebo-task, dosing, patient selection,
or outcome measurements.
2) Short-comings of the modality used.
3) A lack of efficacy for adaptive cognitive training in general.
1.8 Intervention 2: Mindfulness meditation
In a “state of mindfulness,” a person becomes purposefully and nonjudgmentally aware of
the present moment by learning acceptance and how to be actively present.48 Mindfulness is rooted
in Buddhist philosophy and has various implementations in medical literature. Mindfulness
meditation practice focuses attention on one’s own breathing while increasing awareness of the
streams of information of both internal and external stimuli.48
The purpose of mindfulness training is the deactivation of the default mode network. 49,50
The default mode network consists of the hippocampus and its connections to the posterior
cingulate cortex and precuneus posteriorly, and its connections to the anterior cingulate cortex and
mesial frontal lobes anteriorly.50 It is thought to consist of self-generated thoughts including uncued memories and day-dreaming.50 Default mode network can be thought of as “internal
attention” compared to the dorsal attention network51 engaged in the Dual N-Back task.50 A loss of
anticorrelation between these two networks can cause problems with attention.50 Most commonly
12

practiced forms of meditation seem to reduce default mode network activity leading to improved
attentional function.50
1.9 Combining the two interventions
Combining the two interventions, one which activates the dorsal attention network and the
other which deactivates the counter-correlated network, may create a synergistic effect which may
be more efficacious than the other two methods on their own.
1.10 Designing the experiment:
1.11 Our experiment
We hypothesize that subjects with mild vascular cognitive impairment (mild-VCI) who
receive combined Dual N-Back and Mindfulness Meditation Practice (MMP) will have improved
executive functioning capacities compared to those treated with placebo.
Primary outcome is executive functioning capacity, and it is defined as mean change in
executive functioning scores from baseline to one-year post-treatment initiation, as measured
through Alzheimer's Disease Neuroimaging Initiative (ADNI)- Executive Function (ADNI-EF)
test. The mean changes will be reported as a Z score.
Secondary aims include the following:
1) Show increased connectivity in the high-performance network as defined by
connectome predictor modeling (CPM) methodology.
2) Explore improvements in other neuropsychological parameters.
1.12 An imaging biomarker: A network approach to CSVD
A network is a representation of a number of interconnected objects with nodes
representing the objects and the edges representing the connections.52,53 The degree of connectivity
may be represented by connection strength.52,53 We can simplify the relationship between the
different cortical and subcortical structures connected by white matter tracts we discussed in the
last section in terms of a network.

52,53

We can then explore the relationship between individual

connection strength and the ability to perform a particular task.52,53 This network may then be
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simplified by keeping only those edges that have a high positive or negative correlation with the
performance of the particular task in question.52,53 These can respectively be called highperformance network and low-performance network.52,53 Strengthening of low-performance
network could potentially diminish behavioral performance, despite stability in high-performance
networks. It is theoretically possible by manipulating the strength of connections in the network to
change performance.52,53

1.13 Definitions or Terminology
1) VCI is the spectrum of the cognitive disorder that ranges from mild cognitive impairment
(MCI) to dementia.2
2) MCI-CSVD: Mild cognitive impairment due to cerebral small vessel disease.
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Chapter 2 - Review of the Literature
2.1 Background
Cerebral small vessel disease is an understudied population. The medical community
still has more to learn about its pathophysiology, and its diagnostic criteria is still being refined.
We know that CSVD disrupts the frontal-subcortical circuitry1 and can present with deficits in
executive functioning, mentation speed, memory retrieval, and attention2, along with other
impairments, but we do not currently know how to best treat this disease.
2.2 Objectives
In this literature review, we will be assessing the clinical efficacy of Mindfulness
Meditation and Dual N-Back versus an active-placebo control group on delaying executive
functioning decline in people with MCI-CSVD. We will also review Donepezil and other
nonpharmacological interventions that are being studied on trying to improve cognitive
functioning in MCI disease.

2.3 Methods: Criteria for considering studies for this review
2.4 Search Methods and Selection Criteria
We searched ClinicalTrials.gov and Cochrane databases up until July 1, 2018, to identify
relevant, peer-reviewed, primary articles of clinical RCT’s and systematic reviews of nonpharmacological interventions in the treatment of VCI; treatments in CSVD population was too
narrow of a search.
In ClinicalTrials.gov, the terms “Vascular Cognitive Impairment,” “Cognitive
dysfunction,” “Cognitive decline,” and “Vessel” were used. We searched for completed, clinical
trials with published results and found only four studies. The interventions used were NA-13, a
peptide that is designed to reduce ischemic brain damage in post-stroke patients, vitamin B4, calfblood called Actovegin,5 and blood pressure control by prescribing lisinopril, candesartan, or
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hydrochlorothiazide.6 No non-pharmacological interventions populated, so studies from this
search were not used.
In Cochrane database, we used the MeSH Terms “Cognitive Dysfunction (vascular
cognitive impairment),” “Dementia,” and “Vascular (subcortical dementia).” We included all
randomized trials of non-pharmacological interventions that are relevant to current practice
guidelines in MCI treatment.7 The interventions outcomes had to include cognition or
anxiety/stress. All trials selected must have had published results.

2.5 Types of Participants
Participants were either cognitively healthy or elderly with MCI or dementia due to AD
or VAD. Studies that included healthy participants were to study the intervention’s effects on
synaptic plasticity.

2.6 Types of Interventions
Cognitive Training. We included studies that used Dual N-Back or other similar forms of
adaptive cognitive training. Interventions could be delivered individually or in groups. The
studies included come from Cochrane: “Cognitive training and cognitive rehabilitation for
persons with mild to moderate dementia of the Alzheimer's or vascular type: a review”8 and from
“Benefits of Cognitive Treatments Administered to Patients Affected by Mild Cognitive
Impairment/Mild Neurocognitive Disorder.”9
Mindful Meditation Practice. We included trials that used MBSR or its modified
versions.
Donepezil. We included all randomized, double‐blinded trials that compared donepezil
with placebo. Participants enrolled had VCI, which had to be confirmed by either NINCDS‐
ADRDA or DSM‐IV criteria.
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2.10 Types of Outcome Measures
We assessed the following outcomes when applicable. Please refer to the appendix section for
more information on the studies that are included in this review.

1)
2)
3)
4)
5)

Interventions effects on executive functioning scores
Interventions effects on stress
Interventions effects on brain activity assessed by imaging
Interventions effects on other neurocognitive or behavioral domains
Connectome Predictor Modeling

2.11 Results
2.12 Description of studies: Cognitive training, MMP, and Donepezil
Only one study was identified that compared MMP, cognitive training, and Donepezil’s
effects on cognition in the elderly with mild-to-severe AD (Quintana-Hernández DJ).10 The twoyear, double-blinded RCT was an equivalency and non-inferiority study that compared MMPDonepezil to Cognitive Stimulation Training (CST)-Donepezil and Donepezil-only in delaying
cognitive decline in AD. The study enrolled 168 patients with mild-to-severe AD that was
confirmed by the NINCDS-ARDA criteria. The inclusion criteria limited the trial to patients who
were older than 65 years-old, scored between 3-5 points on the GDS, and never had been
prescribed Donepezil before. The study controlled for education, age, APOE biomarker, HTN,
diabetes, dyslipidemia, psychiatric diseases, antidepressants, and anxiolytics. Some of the
exclusion criteria included dementia or behavioral disorders like agitation.
Risk of bias: The effects of the intervention appear to be true since there were no baseline
differences across groups in cognition, sociodemographic factors, or clinical variables. The study
blinded participants by making them unaware of the other non-pharmacological interventions.
Outcomes may be affected by informational biases, as MMP was the only single-blinded
procedure because class sessions were conducted by the main researcher.
Effects of intervention: The MMP-Donepezil group had significantly higher CAMCOG
and MSSE scores in comparison to the Donepezil-only group and was equivalent in scores to the
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CST-Donepezil group (Repeated-measures, p<0.05).10 CAMCOG and MMSE measure spatial
memory, language, memory, perception, attention, and praxia.10

2.13 Description of studies: Combined MMP and Dual N-Back
Only one study was identified that studied MMP and Dual N-Backs’ effects on attention
and worrisome behavior (Course-Choi).11 The weeklong, non-clinical RCT enrolled 86 healthy
adults with worrisome traits and randomized 15 participants to MMP-Dual N-Back, 15
participants to the sham-control group (non-adaptive 1-back task), 15 participants to MMP, and
15 participants to Dual N-Back. The inclusion criteria limited the trial to participants who were
older than 17 years-old and scored higher than 44 on the Pennsylvania State Worry Questionnaire
(PSWQ). The study controlled for baseline differences in PSWQ scores, age, and gender.
Risk of bias: The effects of the intervention appear to be true because the study was
single-blinded, participants were randomized, and intention-to-treat analyses were run. The
observed outcomes
are more likely true because the study controlled for baseline differences in worrisome and
attention scores and sociodemographic variables, but it did not control for baseline differences in
prior experiences with MMP or Dual N-Back. The study found a near significant correlation
between trait worry scores and Dual N-Back performance: Individual differences in performance
could have affected results at a group level, preventing the between group’s analysis from
detecting significance. Also, the study was short and training times are associated with greater
cognitive gains.12 However, worry score outcomes may be over-estimated because they were
measured by STAI (self-reports). In addition, practice-effects in the active-control group could
have confounded results.
Effects of intervention: Combined MMP and Dual N-Back suggest long-term positive
benefits in improving anxiety traits in young healthy adults (t(14) = 5.35, p < 0.001).11
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2.14 Description of studies: Adaptive Cognitive Training
Studies conducted by Willis13, S. Salminen, T. (2016)14 Zhang, Y.15 and Salminen
(2016)16 were included in this review. Willis, Salminen, and Salminen, T. (2016) conducted
single-blinded RCT’s, while Zhang’s randomization and blinding methods were not disclosed.
Willis13 conducted a large-scale trial that examined cognitive trainings effects in healthy,
elderly participants. The studies outcomes were improvements in functional performance and
cognition five-years, post-cognitive training. The study enrolled 2802 participants aged 65 years
or older. The inclusion criteria limited the trial to participants who had mild functional
impairments (<2 ADL disabilities), MMSE scores >23, and were unlikely to have dementia. The
study controlled for sex, education, age, health status, and MMSE and Short-Form-36-Physical
Function scores.13
Salminen (2016)14’s RCT examined Dual N-Back’s effects on executive functioning
gains in the elderly. The study enrolled 47 healthy, elderly participants aged 55 years or older.
The inclusion criteria limited the trial to participants who had MMSE scores >28, MehrfachwahlWortschatz-Intelligenz test scores >110, and participants who did not have visual or auditory
impairments. The study controlled for cognitive differences at baseline, years of education, age,
gender, and hand dominance.
Zhang, Y.15 conducted an investigational trial that first assessed if there are functional
connectivity differences between controlled, Type-II Diabetics (T2DM) and euglycemics, and if
single-back could modify working memory (WM)’s functional systems. The study enrolled 20
cognitively healthy, T2DM and enrolled 19 matched euglycemic patients. The inclusion criteria
limited the study to T2DM without complications, MMSE scores >27, and participants had to
screen negative for metabolic syndromes, cerebrovascular events, and history of substance
use. The study controlled for clinical variables (HbA1c, lipid panel, and HTN), cognitive status
(MMSE scores), initial performance on Dual N-Back, symptoms of anxiety and depression
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(Self-Rating Anxiety Scale and Self-Rating Depressive Scale), Short-term memory
performance (AVLT Test scores), age, gender, and education.
Salminen, T. (2016)16’s RCT assessed Dual N-Back’s effects on white matter integrity in
healthy participants. The study enrolled 56 participants and randomized 20 participants to Dual
N-Back, 18 participants to single-back active control group, and 18 participants to the control
group-no contact. The study did not discuss its inclusion criteria in detail, but it did reference
enrolling people with normal vision and hearing and right-hand dominance. The study controlled
for age, sex, and baseline performance scores.
Risk of bias: The effects of the interventions appear to be reliable because the studies
included were randomized, single-blinded, and ran intention-to-treat analyses, except for the
investigational study. There were also no baseline differences across groups in age, gender,
education, clinical variables, cognitive variables, and adherence to protocol.
Willis reported a 67% retention rate by the end of the five-year study, but the missing
data did not significantly affect result outcomes, as supported by the multiple-imputation
calculation on missing data.13 Due to the large sample size, Willis’s study should have
determined if a smaller sample size could have detected significant results.13
Salminen (2016) found significant improvements in executive functioning scores in the
elderly Dual N-Back group. To show that Dual N-Back caused this effect, he ran a MANOVA,
which was found to be significant (Group x Session x Age, F(10, 67) = 3.38, p < .005, η2 p =
.34).14
Zhang, Y. supported significant findings by running statistical analyses. He confirmed
that the increase in brain activity was occurring in WM systems by running a voxel-wise onesample t-test across the spatial components of the WM networks (p<0.05). 15 The inclusion of
the component analysis also strengthened the study’s findings because it can reveal hidden
factors that underlie sets of random variables, measurements, and signals.15 The study may have
selection bias because it did not discuss blinding.
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Salminen, T. (2016) used only quality images in his study, but outcomes may have been
affected by not controlling for baseline differences in white matter integrity between groups.16
Effects of the interventions: Willis’s study found that Memory (effect size, 0.23 [99%
CI, 0.11-0.35), speed-processing (0.76 [99% CI, 0.62-0.90), and reasoning training (effect size,
0.26 [99% CI, 0.17-0.35]) may be able to improve and maintain higher scores within those
cognitive domains 3-5 years post-training in elderly individuals.13
Salminen (2016)’s study found that Dual N-Back can significantly improve executive
functioning post-test scores in the elderly who are cognitively healthy. Scores may be
comparable to that of a young adults’ who has not received training (M = 1.64 and M = 2.34,
respectively), [t (43) = −7.24, p < .001, Cohen’s d = 2.14).14
Zhang, Y.’s study found that in the setting of WM functional dysconnectivity, singleback might be capable of recruiting other brain regions to complete working memory tasks. This
is supported by the significant correlation that was observed between improved AVLT scores and
increased levels of activity found in the left ventral lateral prefrontal cortex
(t = 3.432, P = 0.001, effect size [ES] = 0.793), the inferior parietal lobule
(t = 2.901, P = 0.006, ES = 0.936), and the right fronto-parietal network (t = 3.115, P = 0.004,
ES = 1.002), despite them being significantly lower during the 1-back task (P < 0.05, Alphasim
corrected).15 These findings may be applicable to people with CSVD because both study
populations share right-frontoparietal network dysconnectivity. The right-frontoparietal network
is associated with execution control, attention and working memory. The study’s findings
support previous trials that support U-shape compensatory mechanisms, which have been
reported in AD participants. 17
Salminen, T. (2016)’s study found that Dual N-Back can significantly increase white
mater integrity in the superior and inferior longitudinal fasciculi (SLF), the inferior frontooccipital fasciculus, the forceps minor (FM), and the corticospinal tract in healthy, young adult
participants (p<0.05).16 The SLF is associated with informational processes between frontal and
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parietal regions; and, the FM is associated with supporting communication between frontal areas.
We cannot discern if the increase in FA values is due to an increased amount of myelination or
axon density in the bundle fibers. The lack of significance between increased FA values and
improved Dual N-Back performance may be due to the short duration of the study. Anatomical
changes, like performance gains, could be dependent on amount of training sessions.

2.15 Description of studies: Mindfulness Meditation
Three studies on MMP were identified that examined its effects on anxiety levels,
synaptic plasticity, and/or cognition. The studies included were by Hölzel, B.18 Wetherell, J,19
and Newberg.20
Hölzel conducted a double-blinded, RCT that assessed whether MMP can alleviate
anxiety symptoms and induce neuroplastic changes in young adults with anxiety disorders. The
study enrolled 29 participants, and the DSM-IV was used by clinicians to confirm the diagnosis.
The study randomized 15 participants into MBSR and 14 participants into the control groupstress management education class. The inclusion criteria limited the study to right-handed
dominance, little experience with mediation (<10 sessions in one’s life-time), participants who
could undergo f-MR imaging, and participants who were either not taking SSRI’s or have been on
a stable dose for at least two months. The study controlled for age, gender, education level,
comorbid anxiety diseases, and SSRI’s.
Wetherell conducted a single-blinded, RCT that assessed whether MMP can alleviate
anxiety and improve mild neurocognitive dysfunction in the elderly. The study enrolled 103
older adults with anxiety or depressive disorders and subjective cognitive impairment.
Depression and anxiety disorders were confirmed by clinicians using the DSM-IV. The study
randomized 56 participants into the control group-health education class and 47 participants into
MBSR. The inclusion criteria limited the study to people who have clinically diagnosable
anxiety or depression disorders (assessed by the DSM-IV and Patient-Reported Outcomes
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Measurement Information System PROMIS test scores), subjective cognitive dysfunction, scores
less than 10 on the Short-Blessed test, deny psychotic or substance use disorders, and participants
who were either not taking anxiolytics or have been on a stable dose for greater than one month.
The study controlled for age, clinical variables, gender, education, medications that can affect
mood and cognition, cognitive differences at baseline (assessed by the PROMIS scale, Wechsler
Test of Adult Reading, Digit Span subtest, Grooved Pegboard Test, Memory composite test, and
Cognitive control composite test), prior experiences with mindfulness or yoga practice, and
regular use of corticoid steroids.
Newberg conducted a single-blinded, RCT that assessed whether Kirtan Kriya can
improve cognitive scores and increase cerebral blood flow (CBF). The study enrolled 14
participants with MCI, which was confirmed by NINCDS-ADRD.20 The study randomized 7
participants into Kirtan Kriya and 7 participants into the control group-music group. The
inclusion criteria limited the study to participants who were older than age 60, scored >16 on the
MMSE, and had no prior experiences with meditation or yoga. The study controlled for age,
cognitive outcome measures, and prior experience with meditation or yoga. However, the study
did not control for anxiety or other psychiatric diseases or baseline differences in CBF.
Risk of bias: The effects of the interventions appear to be reliable because the studies
sampled participants randomly, were blinded, randomized participants to either MBSRB or a
control group, and ran intention-to-treat analyses. There were no significant differences across
groups in age, gender, education level, comorbid anxiety diseases, SSRI’s, or adherence to
protocol. SSRI’s typically take about six weeks to reach a steady-state, so both studies controlled
for this well by excluding participants who have been on an SSRI less than one month.
Hölzel’s study ensured that the differences observed in BOLD signals between groups
where not due to baseline differences in brain activity by running a post-hoc analysis (p>0.05).18
When the study enrolled healthy participants for comparison data, the inclusion criteria controlled
for confounding variables by excluding people with any anxiety or other psychological traits and
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if they had been recently on any medications that would alter cerebral blood flow. BAI outcomes
may be overestimated due to self-reporting biases, and the novelty of MRI imaging could have
confounded outcomes as well. Over-estimation of BAI scores appears less likely since Perceived
Stress Scale scores were not significantly correlated to changes in BOLD signal.18 To avoid overestimations, changes in stress could have been quantified by measuring am serum cortisol levels.
Wetherell’s study had a low percentage of missing data, approximately 1%.19 The study
showed that the missing data did not significantly affect outcomes by running the Missing Value
Analysis add-on module (χ2 = 15.7, P = .61).19 The findings may not be applicable to elderly
with cognitive impairment since the diagnosis of MCI was subjective. Outcomes on anxiety
scores could be over-estimates since they were measured by self-reported results, but this is
unlikely because significant changes in cortisol levels were observed.
Newberg ran a False Discovery Rate - multiple comparisons to verify that the significant
changes in cerebral blood flow in the intervention group were accurate. Also, there were no
significant differences between groups in adherence to protocol: both groups adhered about 75%
to protocol.20 Outcomes may be affected however because the study did not control for baseline
differences in CBF or control for psychiatric diseases.
Effects of intervention: The results of both studies are applicable to people with anxiety
because diagnoses were confirmed by the DSM-IV.
Hölzel’s study found that MMP significantly lowers BAI scores, increases BOLD activity
in the right pars opercularis, left pars triangularis, and right rostral middle frontal cortex, and
increases the right amygdala’s functional connectivity with the left rostral middle frontal cortex
(ρ = − .648, p < .001), the right rostral middle frontal cortex (ρ = − .487, p = .018), and the right
superior frontal cortex (ρ = − .424, p = .044) (ANOVA group-by-time interaction and Spearman's
ρ (0.05).18 Therefore, MMP can modify functional connectivity. MMP’s ability to increase
activity in the VLPFC activity could be significant because higher activity has been observed in
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the VLPFC during Cognitive Behavioral Therapy and on SSRI’s, which are standards of care in
anxiety treatment.21 These results are applicable to cognitively, healthy adults.
Wetherell’s study found that MMP significantly improves memory functioning and
alleviates anxiety in the elderly with GAD and subjective cognitive impairment (p<0.05).19 The
study showed that a meaningful relationship exists between cognition and anxiety by finding a
significant correlation between improvements in anxiety and memory scores ((χ21 =4.5, P = .03),
along with a significant decrease in cortisol levels in the MMP group (paired t = 3.8, P = .0015).19
The study did not find significant improvements on executive functioning scores (DSST). To
bolster its findings, the study also should have run a regression analysis between anxiety scores
and cortisol levels and between cognitive scores and cortisol levels. Measuring cortisol levels is a
more accurate way to measure stress, and we can further study its effects on increasing amygdala
activity and suppressing Brain-derived neurotrophic factor (BDNF), a factor that modulates
neuronal survival and regulates synaptic plasticity.22
Newberg’s study found that Kirtan Kriya caused significant changes in CBF and
improvements on the following test measures: Right prefrontal cortex - Trails B task (R = −0.61,
p = 0.02), left thalamus - Trails B task (R = −0.62, p = 0.02) and, left thalamus - Digit Span Test
(R = 0.56, p = 0.02).20 Listening to a neutral-stimuli served as a good control because no
significant changes in outcomes were observed on neuropsychological tests, cerebral blood flow,
and correlations between test scores and blood flow. More importantly, the active-control group
did not affect observed outcomes in the intervention group.

2.16 Description of studies: Donepezil
Studies conducted by Chen, X23., Wilkinson, D. 24, and Black, S.25 were included in this
review. The studies were double-blinded, RCT’s that compared Donepezil to a placebo group.
Wilkinson and Black enrolled participants with probable MCI-due to VCI, with diagnoses
confirmed by NINDS-AIREN criteria. Chen enrolled participants with probable MCI-due to AD,
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which was assessed by using neuropsychological tests. A score of 1SD below age-adjusted
normative values on at least one memory and learning test was defined as probable-MCI. There
are varieties of different tests that can assesses this, but Chen used the Hopkins Verbal Learning
Test–Revised, Mattis Dementia Rating Scale: Memory subscale, Wechsler Memory Scale–III:
Logical Memory, and Brief Visuospatial Memory Test–Revised tests.
Chen’s study examined if Donepezil could enhance cerebral blood flow in MCI-AD
participants while performing a verbal memory task and HVLT test. The study enrolled 11
participants and randomized six participants to the Donepezil group and five participants into the
placebo group. The inclusion criteria limited the study to participants with subjective and
objective measures of MCI and global cognition scores within normal limits (MMSE average
score was 29). The study screened for vascular diseases and functional deficits to exclude people
with cognitive impairments due to probable VCI or dementia from enrolling. The study
controlled for age, baseline cognitive test scores, education, and gender.
Wilkinson and Black conducted similarly designed studies that assessed whether
Donepezil could improve cognitive scores over a twenty-four-week trial. Wilkinson enrolled 616
participants and randomized 193 participants to the placebo group, 208 participants to Donepezil
5mg/daily group, and 215 participants to Donepezil 10mg/daily group. The inclusion criteria
limited the study to participants who met at least one of the NINDS-AIREN criteria, scored
between 11-25 points on the MMSE, and screened negative for unstable medical conditions and
psychiatric disorders. The study controlled for demographic characteristics, clinical variables,
neuropsychological tests, past cognitive enhancing drug-use, and primary outcomes at baseline.
Black enrolled 603 participants and randomized 199 participants to the placebo group, 198
participants to Donepezil 5 mg/daily group, and 206 participants to the Donepezil 10 mg/daily
group. Black used the same inclusion criteria and controlled for the same variables as Wilkinson.
Both studies also measured the same outcomes, which were mean changes between groups on
ADAS-COG, CIBIC, Alzheimer’s Disease Functional Assessment and Change Scale (ADFACS),
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and Clinical Dementia Rating-Sum of the Boxes (CDR-SB) tests. Wilkinson included MMSE
test scores, while Black did not. Neither trials used tests that directly measured executive
functioning.
Risk of bias: The effects of the interventions appear to be reliable because the studies
sampled participants randomly, were blinded, and randomized participants to either Donepezil or
a control group, and ran intention-to-treat analyses. There were no significant differences across
groups in age, gender, education, CT scan images, cardiovascular risk factors, and
neuropsychological tests.
Chen supported his observations that Donepezil significantly decreased cerebral blood
flow decline during the verbal memory task by running an analysis to detect for cerebral flow
differences at baseline (p<0.05). Selection biases may affect outcomes because MMSE scores of
26 or 27 are typical cut-off scores with similar educational and socioeconomic backgrounds to
avoid missing true cases.26 However, participants did need to score 1 SD below normative scores
in at least 1 cognitive domain.
Wilkinson and Black’s results are applicable to elderly with VCI because the study
confirmed the diagnosis with the NINDS-AIREN criteria. The study’s sample included (33%) of
participants with identified subcortical strokes, so the studies’ results may be applicable to CSVD
as well. Executive functioning deficits are common though in VCI and Donepezil’s effects on
this measure are unknown because it was not directly assessed.
Effects of intervention: Chen’s study found that Donepezil caused less cerebral blood
flow decline in the left temporal by 1.51 ml/min/100g and in the left frontal tissue by 1.69
ml/min/100g in comparison to the control group (p<0.05).23 There were no significant differences
between group scores on these tasks. Therefore, Elderly who have been diagnosed with MCI-due
to AD for six months or less may experience less cerebral decline while performing some
memory tasks and it may improve memory performance scores. People who do not take
Donepezil may maintain memory performance scores for at least six months into their disease.
30

Wilkinson’s study found that elderly persons, who have been diagnosed with mild VCI
for 24 weeks or less, might experience small improvements on global cognitive functioning
assessments on 5 or 10mg of Donepezil in comparison to people who do not take the drug.
Black observed similar smaller effect sizes. At 24 weeks, Black’s study found significant
improvements in baseline ADAS-cog scores and ADFACS Scores in the Donepezil 5 mg/d group
(ADAS-cog effect size = −1.90, p = 0.001; ADFACS effect size = −1.31, p = 0.02) and Donepezil
10 mg/d group (ADAS-cog effect size= −2.33, p<0.001; ADFACS effect size = −1.31, p=0.02).25
Significant improvements in baseline CIBIC-Plus scores were only observed in the donepezil 5
mg/d group (p=0.014), while significant improvements in baseline CDR-SB scores were only
observed in the donepezil 10 mg/d group (p=0.007).25 Both studies showed that Donepezil was
well tolerated by observing no significant differences between groups in adverse side effects and
withdrawal rates (p>0.05).24,25

2.17 Description of studies: Multidomain Intervention Study: Physical Exercise
Ngandu’s multi-domain intervention was included into this review because it was a
double-blinded RCT that enrolled healthy-to-MCI elderly who had similar clinical traits that are
found in CSVD, like HTN and diabetes. MCI was determined by Consortium to Establish a
Registry for Alzheimer's Disease (CERAD) neuropsychological battery test scores, which
assessed memory and recall.
The study assessed if diet, exercise, cognitive training, and metabolic control could
synergistically slow cognitive decline. Cognitive decline was measured by mean change in
baseline NTB (z score) scores over two-years. Secondary outcomes measured changes in
executive functioning, memory, and speed processing scores, and the intervention’s effects on
improving risk of cognitive decline were assessed.
The RCT enrolled 1,190 elderly participants and randomized 591 participants to the
multidomain intervention group and 599 participants to the control group to receive health
31

education. The inclusion criteria limited the study to participants who were between the ages 60–
77 years old, scored a 6 or higher on CAIDE (Cardiovascular Risk Factors, Aging and Dementia)
Dementia Risk Score, and scored 1SD below normative scores on either the MMSE (<26 points),
word-recall list task (<75%), or word-list memory task (19 points).27 The study did not exclude
cognitive impairment possibly due to CSVD. The study controlled for age, education, MMSE
scores, vascular and lifestyle risk factors, and cognitive differences at baseline (NTB total score,
executive functioning, processing speed, and memory).27
Risk of bias: The effects of the intervention appear to be reliable because participants
were randomly sampled, blinded, and randomized. There were no significant differences across
groups in age, education, vascular and lifestyle risk factors, and cognitive scores at baseline. The
drop-out rate was minimum, with only 4% from the multidomain group and 7% from the control
group.27 Missing data was handled by performing modified intention-to-treat analyses. Missing
results did not affect significance, as determined by the re-calculation with intention-to-treat
analysis.27 Outcomes may have been affected by information biases since adherence to protocol
was only self-reported, and practice effects may have confounded outcomes.
Effects of intervention: The study observed a 25% risk of cognitive decline in NTB zscores over two years in the control group. The multidomain approach also improved speed
processing and executive functioning scores (p=0.039) in the intervention group.27 The study did
not compare the different interventions to determine if one was significantly better than another
was. There is a debate as to whether physical exercise versus cerebral blood flow helps
promote cognitive improvement. One review observed moderate gains in memory in elderly
participants without MCI after acute exercise, but the benefits were lost after 14 months.28 The
observed gains may be due to physical exercise stimulating the release of BDNF, nerve growth
factor (NGF), and insulin-like growth factor (IGF-1).29 MMP is another intervention that has been
associated to increase BDNF release.22
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2.18 Review on Instruments of Measurement
2.19 Description of studies: Alzheimer's Disease Neuroimaging Initiative-Executive Functioning
(ADNI-EF) test
The ADNI-EF test is a composite of seven, executive functioning tests. These tests
include Category fluency: Animals and Vegetables, Digit Span Backwards, WAIS-R Digit
Symbol Substitution (DSST), Clock Drawing, and Trails B–Trails A.30 These seven tests were
included into the Vascular Cognitive Impairment Harmonization Standards by the National
Institute for Neurological Disorders and Stroke (NINDS) and the Canadian Stroke Network
(CSN).31 These standards were created to help identify VCI patients for future studies. In the
VCI Harmonization standards, Clock Drawing and Trails-B are considered supplementary test.31
The composite ADNI-EF has only been studied in one trial that began in 2003 and was
supported by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging
and Bioengineering (NIBIB), the Food and Drug Administration (FDA), and private and nonprivate pharmaceutical companies.30 The ADNI-EF study was created to determine if MRI and
PET imaging, biological markers, and neuropsychological assessments could detect the
progression of MCI to AD. The three-year study examined this by trying to determine if a
significant correlation existed between ADNI-EF z-scores and cortical changes on MRI, amyloid
β1-42, total tau, and phosphorylated tau181-P, levels in CSF, and MCI-AD conversion rates.30 The
study sampled participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database and recruited 229 participants with normal cognition (Age 76.0 ± 5.0, N= 229), 397
participants with MCI (n= 390, 74.9 ± 7.5), and 193 participants with AD (n=181, Age=
75.7 ± 7.4).30 The inclusion criteria limited the study to either elderly with healthy cognition,
MCI-due to AD, or AD. The study controlled for age, education, sex, and the presence of one or
more APOE ε4 alleles.30
Risk of bias: The ADNI-EF model appears to be reliable because significance could
have been observed with a 40% smaller sample size and individual test performances do not
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affect outcomes.30 The study found statistical significance on its three validation markers, even
with a reliability curve ranging from 0.85 to 0.75 (p<0.05). 30 MR-imaging was one if its
validation markers and ADNI-EF z-scores were significantly correlated to frontal lobe cortical
thickness (p<0.05).30 The model may have failed to reach higher reliability because the tests
were administered to a study population that is distinctively known to have impairments in
declarative episodic memory.32 The study did not compare the seven tests to determine if one
was significantly better than another, and there is no guarantee that these tests truly measure
frontal lobe executive performance. The significant correlation found between ADNI-EF zscores and frontal lobe cortical thickness helps disprove this. In addition, normal distribution
calculations are more reliable than skewed calculations, which must be calculated on some
neuropsychological tests.
Effects of intervention: ADNI-EF z-scores were significantly correlated with MCI-AD
conversion rates, MRI images from selected brain regions, and levels of amyloid β1-42, total tau,
and phosphorylated tau181P in CSF levels.30 Though VCI participants were not enrolled in the
study, the ADNI-EF composite test may be a useful measurement to assess an intervention’s
effect on improving executive dysfunction.

2.20 Description of studies: Connectome-based predictive modeling (CPM)
CPM is a relatively new technique that receives inputs of connectivity and behavioral
performance data and outputs high and low functional performance networks that are correlated
to high and low behavioral scores. 33 The significant correlation between functional
connectivity and behavioral performance enables the model to predict behavioral outcomes in
that individual subject. The CPM networks can then be trained on new data sets and make
accurate behavioral predictions in new cohorts. CSVD’s white matter damage leads to
dysconnectivity, affecting many functions and brain regions. CPM is well suited to measure
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these dysconnectivity’s and can provide a gestalt measure of executive functioning abilities and
executive dysfunctions in CSVD.
CPM’s methods are still being refined as we learn more about brain networks and
improve computational methods to create more accurate predictor models. The NIH is funding
the Human Connectome Project and has provided open source sharing to allow researchers
assess to templates and protocols to conduct experiments in order to add meaningful data to the
brain mapping project.34 A part of the human connectome project is to identify and learn how
functional networks produce certain behaviors. Behavioral templates that are currently offered
by the NIH are rest, emotion, gambling, language, motor, relational, social, and working
memory.34,35 Executive functioning is not a behavioral task offered. The ADNI-EF can be
completed under MR-imaging and provide meaningful data about functional connectivity in
executive functioning. We will not discuss the CPM protocol because templates are provided
by the NIH34, Nature has published in detail how to perform the CPM computations in
MATLAB33, and an architype of CPM was developed here at Yale in the study of functional
connectivity in attention and Attention Deficit and Hyperactivity Disorder (ADHD). 36
Risk of bias: CPM’S outcomes may be affected by the statistical test chosen to
calculate the connectivity matrix edges. The Nature protocol states that edge calculations can
be made with either Pearson's correlation, Spearman's correlation, or robust regressions. 33 The
ADNI-EF computed its model with robust regressions and calculated a reliability between
0.85 to 0.75.30 The ADHD study computed its edges with “Spearman-Brown-corrected splithalf correlation” and calculated a reliability of 0.975, which is considered excellent.36 Either
regression model would still overestimate or underestimate performances, and therefore, CPM
provides good relative data. The amount of imaging data from participants may also affect
outcomes: the ADHD study enrolled 25 individuals, and the ADNI-EF study’s data comes
from 800 participants. The imaging modality of choice is 3T or 7T magnetic resonance
imaging and a variety of accepted imaging software is available. 34
35

2.21 Description of studies: Diffusion tensor (DTI) and dynamic susceptibility contrast (DSC)
The MRI images that will be used in CPM will come from DTI - DSC sequence
protocols. In accordance with Standards for Reporting Vascular Changes on Neuroimaging
(STRIVE)37 and Fisher criteria,38 lacunar infarcts can be visualized on T1-, T2-FLAIR, and T2weighted sequences on MRI. Functional connectivity is assessed with brain-blood-oxygenationlevel-dependent (BOLD) f-MRI.
Only one studied was identified that visualized leukoaraiosis with 3T BOLD and DTI
MR-imaging (Sam, K.).39 The study tried to assess whether impaired cerebrovascular reactivity
(CVR) is significantly correlated with white mater tissue integrity and evaluated this by using
diffusion and perfusion MR-imaging. The participants were conveniently sampled and 75
patients with moderate to severe leukoaraiosis were enrolled into the study. The inclusion criteria
limited the study to participants who had cortical infarcts or white mater lesions less than two
centimeters, a Fazekas score greater than two, older than fifty-years of age, hemodynamic
instability less than 70%, and no subcortical infarcts within three months of enrollment.
Participants whose BOLD images had motion artifacts were excluded from the study.
The study controlled for poor imaging quality, such as imaging spatial confounds. 39
Risk of bias: The study’s outcomes may be compromised because imaging could not
discern if there were other factors besides ischemia that were causing WMH. The study did
control for head motion artifact and imaging spatial confounds.39 Selection bias of convenience
sampling may also affect outcomes.
Effects of intervention: The study observed that T2-weighted images are less likely to
detect subtle changes in the conversion of normal white mater to WMH.
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2.22 Description of studies: Neuropsychological and behavioral tests
Please refer to the appendix for more information on the neuropsychological and behavioral
tests that are used in this study.

2.23 Effects of interventions on primary and secondary outcomes
Non-pharmacological effect sizes on primary and secondary outcomes that are used in
this study were found in a systematic review on cognitive training. The systematic review was
called “Cognitive training and cognitive rehabilitation for persons with mild to moderate
dementia of the Alzheimer's or vascular type: a review.” Cognitive training was observed to have
a large effect of 7.47 (-14.19, 29.14) on DSST scores in a sample of 153 participants;8 a large
effect of 14.53 (-9.35, 38.41) on Trail-B Test scores in a sample of 77 participants;8 and, a large
effect of 25.26 (-76.70, 26.19) on Trail-A Test scores in a sample of 76 participants.8 On
secondary outcomes, cognitive training had a poor effect size of -0.94 (-3.67, 1.79) on BOLD
activity in a sample of 35 participants;8 and, a poor effect size of 0.03 (-0.34, 0.41) on anxiety
scores in a sample of 114 participants.8 Observing similar effect sizes from cognitive training are
unknown because these measures were not obtained in CSVD participants.

2.24 Conclusion
2.25 Summary of main results
The aim of this review was to evaluate the current evidence regarding the efficacy of
adaptive cognitive training and MMP on improving executive functioning for people with MCICSVD. We included nine studies of adaptive cognitive training and MMP into this literature
analysis, along with two studies on Donepezil and one multi-domain study. These interventions’
effects on executive functioning could not be analyzed because of the variability in outcome
measures across the studies. The high-quality studies included in this review support cognitive
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training and MMP to have the potential to generate small-to-medium effects on executive
functioning.

2.26 Applicability of evidence
Cognitive training and MMP have not yet been studied in MCI-CSVD, so the
interventions’ effects may or may not be reproduced in this study population. Ngandu27 and
Zhang’s15 studies support cognitive training to promote some cognitive improvements in the
elderly with cardiovascular risk factors that would predispose them to lacunar infarcts. 40 The
systematic review on cognitive training in participants with AD or VaD supported small
improvements on some executive functioning tests.8
This review may have missed significant effects because of the limited number of
relevant RCT’s available, the varying terminology that references this study population and the
interventions studied, and because of the included studies methodological limitations.
Limitations in study design include duration of intervention, active versus no-contact groups, and
the use of neuropsychological tests to assess functional performance. Jaeggi found that the
number of treatment doses is directly correlated to behavioral performance gains.12 The standard
number of doses to reproduce effects remains unknown, as it would be individualized for
participants. The superiority of active-control groups over no-contact groups remains unknown.
Participants have received cognitive gains from single-back, so this may serve as a poor control
group, whereas listening to a neutral stimulus may act as a better placebo. Neuropsychological
tests can confound results by Hawthorne and practice effects. The studies included in this review
prevented against Hawthorne affects by administering many versions of the same test. Many
studies administer multiple tests because one neuropsychological test does not accurately assess
functional performance. A better way to measure functional performance is to calculate the
correlation between neuropsychological test scores and micro-structural or functional changes on
imaging, assessed by DTI- DSC and BOLD.
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2.27 Disagreements with other studies
The current “Grade A” recommendation in the treatment of MCI is to discuss with
patients the options of cholinesterase inhibitors.7 The evidence does not support the
administration of Donepezil to be a Grade A practice. The studies failed to assess the
interventions effects on the disease’s most common deficit, executive functioning. Instead, both
studies administered tests that are commonly used in AD studies. Furthermore, when Donepezil
was studied in the elderly with MCI-due to AD, the placebo group maintained their memory
performance scores over the six-month period and no significant differences were observed
between the two groups.

2.28 Implications for research
The high-quality studies offered in this review support combined MMP and adaptive
cognitive training (Dual N-Back)’s beneficial effects on cognition. However, this cannot be
confirmed until a well-designed, single-blinded RCT is conducted in this population.
Furthermore, the use of CPM and imaging will allow us to measure these interventions’
effectiveness on functional and executive functioning performance. The literature review
supports the need for this current study to be conducted.
2.29 Key Terms
VaD: vascular dementia; Subcortical ischemic vascular dementia; Lacunar infarction; Vascular
factor; Cerebrovascular disease; MCI: mild cognitive impairment; AD: Alzheimer's disease;
Carotid stenosis; Dementia; Anxiety; Stress; Agitation; Depression; CIND: Center for Imaging of
Neurodegenerative Diseases; NPI: Neuropsychiatric Inventory; Cognitive intervention; Cognitive
training; Mindfulness-based stress reduction; Mind–body interventions; Mental stimulation;
fMRI: functional magnetic resonance imaging; CDSR: Cochrane Database of Systematic
Reviews; RCT: randomized controlled trial; Treatment
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MeSH terms: Cognitive Dysfunction/diagnosis*, Dementia, Vascular/classification, Dementia,
Vascular/diagnosis*, Dementia, Vascular/etiology, Cognitive Dysfunction; MeSH terms:
Brain/diagnostic imaging*, Cognition/physiology, Diffusion Tensor Imaging/methods, Machine
Learning, Memory, Neural Pathways/diagnostic imaging, Neuronal Plasticity/physiology*, White
Matter/physiology*, Short-Term/physiology*; MeSH terms: Anxiety/therapy*, Mind-Body
Therapies*, Mindfulness*, Stress, Psychological/therapy*
References
1.

2.
3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

Reed BR, Eberling JL, Mungas D, Weiner MW, Jagust WJ. Memory Failure Has
Different Mechanisms in Subcortical Stroke and Alzheimer’s Disease. Annals of
neurology. 2000;48(3):275-284.
Jokinen H, Kalska H, Mantyla R, et al. Cognitive profile of subcortical ischaemic
vascular disease. J Neurol Neurosurg Psychiatry. 2006;77(1):28-33.
Hill MD, Martin RH, Mikulis D, et al. Safety and efficacy of NA-1 in patients with
iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised,
double-blind, placebo-controlled trial. Lancet Neurol. 2012;11(11):942-950.
Thaipisuttikul P, Galvin JE. Use of medical foods and nutritional approaches in the
treatment of Alzheimer’s disease. Clinical practice (London, England). 2012;9(2):199209.
Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn AD. ARTEMIDA Trial (A
Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A
Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke
Cognitive Impairment. Stroke. 2017;48(5):1262-1270.
Hajjar I, Hart M, Chen YL, et al. Effect of antihypertensive therapy on cognitive function
in early executive cognitive impairment: a double-blind randomized clinical trial. Arch
Intern Med. 2012;172(5):442-444.
Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild
cognitive impairment: Report of the Guideline Development, Dissemination, and
Implementation Subcommittee of the American Academy of Neurology. Neurology.
2018;90(3):126-135.
Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for
persons with mild to moderate dementia of the Alzheimer's or vascular type: a review.
Alzheimer's Research & Therapy. 2013;5(4):35.
Cavallo M, Signorino A, Perucchini ML. Benefits of Cognitive Treatments Administered
to Patients Affected by Mild Cognitive Impairment/Mild Neurocognitive Disorder. Drug
Development Research. 2016;77(8):444-452.
Quintana-Hernández DJaM-B, María T.b | Ibáñez-Fernández, Ignacio J.b | Pino, Angelo
Santana-delc | Quintana-Montesdeoca, María P.c | Rodríguez-de Vera, Bienvenidad |
Morales-Casanova, Davide | Pérez-Vieitez, María del Carmenf | Rodríguez-García,
Javierg | Bravo-Caraduje, Noeliag. Mindfulness in the Maintenance of Cognitive
Capacities in Alzheimer’s Disease: A Randomized Clinical Trial. Journal of Alzheimer's
Disease. 2016;50(1):217-232, 2016.
Course-Choi J, Saville H, Derakshan N. The effects of adaptive working memory training
and mindfulness meditation training on processing efficiency and worry in high worriers.
Behaviour Research and Therapy. 2017;89(Supplement C):1-13.
Jaeggi SM, Buschkuehl M, Jonides J, Perrig WJ. Improving fluid intelligence with
training on working memory. Proceedings of the National Academy of Sciences.
2008;105(19):6829-6833.

40

13.

14.
15.

16.
17.

18.

19.

20.

21.

22.
23.

24.
25.

26.

27.

28.

29.

Willis SL, Tennstedt SL, Marsiske M, et al. Long-term Effects of Cognitive Training on
Everyday Functional Outcomes in Older Adults. JAMA : the journal of the American
Medical Association. 2006;296(23):2805-2814.
Salminen T, Frensch P, Strobach T, Schubert T. Age-specific differences of dual n-back
training. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2016;23(1):18-39.
Zhang Y, Lu S, Liu C, et al. Altered brain activation and functional connectivity in
working memory related networks in patients with type 2 diabetes: An ICA-based
analysis. Scientific Reports. 2016;6:23767.
Salminen T. Increased integrity of white matter pathways after dual n-back training.
NeuroImage. 2016;133:244-250.
Yetkin FZ, Rosenberg RN, Weiner MF, Purdy PD, Cullum CM. FMRI of working
memory in patients with mild cognitive impairment and probable Alzheimer's disease.
Eur Radiol. 2006;16(1):193-206.
Holzel BK, Hoge EA, Greve DN, et al. Neural mechanisms of symptom improvements in
generalized anxiety disorder following mindfulness training. Neuroimage Clin.
2013;2:448-458.
Julie Loebach Wetherell P, b,*; Tamara Hershey, PhDc; Steven Hickman, PsyDb; Susan
R. Tate, PhDb; David Dixon, PhDc; Emily S. Bower, MAd; and Eric J. Lenze, MDc.
Mindfulness-Based Stress Reduction for Older Adults With Stress Disorders and
Neurocognitive Difficulties: A Randomized Controlled Trial. J Clin Psychiatry.
2017;78(7):e734–e743.
Newberg AB, Wintering N, Khalsa DS, Roggenkamp H, Waldman MR. Meditation
effects on cognitive function and cerebral blood flow in subjects with memory loss: a
preliminary study. J Alzheimers Dis. 2010;20(2):517-526.
Maslowsky J, Mogg K, Bradley BP, et al. A preliminary investigation of neural correlates
of treatment in adolescents with generalized anxiety disorder. J Child Adolesc
Psychopharmacol. 2010;20(2):105-111.
Gray JD, Milner TA, McEwen BS. Dynamic plasticity: the role of glucocorticoids, brainderived neurotrophic factor and other trophic factors. Neuroscience. 2013;239:214-227.
Chen X, Magnotta VA, Duff K, Boles Ponto LL, Schultz SK. Donepezil effects on
cerebral blood flow in older adults with mild cognitive deficits. J Neuropsychiatry Clin
Neurosci. 2006;18(2):178-185.
Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia. A randomized,
placebo-controlled study. 2003;61(4):479-486.
Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in
vascular dementia: positive results of a 24-week, multicenter, international, randomized,
placebo-controlled clinical trial. Stroke. 2003;34(10):2323-2330.
Kukull WA, Larson EB, Teri L, Bowen J, McCormick W, Pfanschmidt ML. The MiniMental State Examination score and the clinical diagnosis of dementia. J Clin Epidemiol.
1994;47(9):1061-1067.
Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet,
exercise, cognitive training, and vascular risk monitoring versus control to prevent
cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The
Lancet.385(9984):2255-2263.
Roig M, Nordbrandt S, Geertsen SS, Nielsen JB. The effects of cardiovascular exercise
on human memory: A review with meta-analysis. Neuroscience & Biobehavioral
Reviews. 2013;37(8):1645-1666.
Voss MW, Prakash RS, Erickson KI, et al. Plasticity of Brain Networks in a Randomized
Intervention Trial of Exercise Training in Older Adults. Frontiers in Aging Neuroscience.
2010;2:32.

41

30.

31.

32.
33.
34.
35.

36.
37.

38.
39.
40.

Gibbons LE, Carle AC, Mackin RS, et al. A composite score for executive functioning,
validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with
baseline mild cognitive impairment. Brain Imaging and Behavior. 2012;6(4):517-527.
Hachinski V. National Institute of Neurological Disorders and Stroke-Canadian Stroke
Network vascular cognitive impairment harmonization standards. Stroke (1970).
2006;37(9):2220-2241.
Markowitsch HJ, Staniloiu A. Amnesic disorders. Lancet. 2012;380(9851):1429-1440.
Shen X, Finn ES, Scheinost D, et al. Using connectome-based predictive modeling to
predict individual behavior from brain connectivity. Nature Protocols. 2017;12:506.
NIH Blueprint for Neuroscience Research. The Human Connectome Project. 2018.
https://www.neuroscienceblueprint.nih.gov/connectome/index.htm
Finn ES, Scheinost D, Finn DM, Shen X, Papademetris X, Constable RT. Can brain state
be manipulated to emphasize individual differences in functional connectivity?
NeuroImage. 2017;160:140-151.
Rosenberg MD, Finn ES, Scheinost D, et al. A neuromarker of sustained attention from
whole-brain functional connectivity. Nature Neuroscience. 2015;19:165.
Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into
small vessel disease and its contribution to ageing and neurodegeneration. The Lancet
Neurology. 2013;12(8):822-838.
Fisher CM. LACUNES: SMALL, DEEP CEREBRAL INFARCTS. Neurology.
1965;15:774-784.
Sam K, Peltenburg B, Conklin J, et al. Cerebrovascular reactivity and white matter
integrity. Neurology. 2016;87(22):2333-2339.
Blanco PJ, Müller LO, Spence JD. Blood pressure gradients in cerebral arteries: a clue to
pathogenesis of cerebral small vessel disease. Stroke and Vascular Neurology.
2017;2(3):108-117.

42

Chapter 3 - Study Methods
3.1 Study Design
The present study will be implemented as a two-arm superiority, single-blinded
randomized control trial (RCT) that will randomize and allocate participants with MCI-CSVD
into either the control group who will engage in placebo (solitaire and music listening) per day or
into the experimental group to receive mindfulness meditation and Dual N-Back to assess its
efficacy in slowing the progression of executive dysfunction.
3.2 Synopsis
- Ninety-seven people will be recruited and consented after screening for eligibility. We will be
screening for vascular cognitive impairment due to small vessel disease phenotype rather than
large vessel disease.
- Subjects with anxiety, depression and alternative diagnoses will be ruled out.
- They will be randomized to a low intensity (placebo group) and high intensity intervention
group.
- The low intensity group includes playing solitaire for half an hour and listening to music for
another 30 minutes – daily.
- The high intensity intervention group consists of playing Dual N-Back for 30 minutes and
meditating for 30 minutes – daily. There are group sessions three times per week which are
required for the first two weeks of enrollment but voluntary from then on.
- Each subject will be in the study for 12 weeks after which a voluntary subset may decide to
continue the routine for future studies and measurements.
- Imaging and neuropsychological testing is performed at baseline and at the end of the 12 weeks.
- Primary endpoint is changes in Alzheimer's Disease Neuroimaging Initiative (ADNI)- Executive
Function (ADNI-EF) composite measure. Secondary endpoints include changes in
neuropsychological scores and changes in connectivity, especially in the sub-graph of the
connectome that correlates with executive function.
3.3 Recruitment
Our sample size for this study is 74 participants. However, we will enroll 97 participants
because we expect a 30% drop-out rate based off other MCI studies that involved physical
exercise in the ederly. 1 Sample size was calculated with G*Power 3.1.9.2 software and a priori
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power analysis computed that 74 participants would be needed to determine a significant difference
between two groups, with the study set at a 5% significance level, powered at 80%, and effect size
F of 0.25. Please refer to the appendix to view sample calculation.
The source population is elderly people with VCI due to CSVD without mood disorders.
Our sources of referral will include Yale Memory Clinic, Yale Stroke Center, Adler Geriatrics
Centre, and Yale Program on Aging. We will ask physicians to participate and to help provide
referrals. For those physicians who agree to participate, we can help them identify appropriate
referrals to our study by asking Epic’s Joint Data Analytics Team to cross reference VCI, white
matter disease, lacunar infarct, vascular dementia and CSVD with participating physicians. We
will post an advertisement of our study on the Help Us Discover Now site. The advertisement will
ask for elderly people with MCI due to cardiovascular risk factors, like stroke or DM, to participate
in a study that is trying to slow the progression of cognitive decline. Identified individuals will
present to Church Street Research Unit for eligibility screening.

3.4 Study population
We will be enrolling both men and women equally into our study, and we expect to enroll
ethnicities that are more prevalent in the state of CT, which are Caucasians, African-Americans,
and Hispanics. Participants must be English-speaking.

3.5 Inclusion Criteria
1) Participants need to be between the ages 50 to 89 years-old with MCI due to vascular
pathology according to VASCOG criteria.2
2) The cognitive deficit should be subcortical, more than cortical, suggesting small rather than
large vessel disease pathology.
3) Study partner should confirm cognitive decline.
4) Relative novice to cognitive training and meditation.
5) Possession of a smart phone or computer to run the Dual N-Back program on.
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3.6 Exclusion Criteria
1) Drug or alcohol substance misuse
2) Use of medications that affect cognition within 30 days of the study
3) Exclude patients with depression and anxiety
4) Major neuropsychiatric conditions such as Parkinson’s disease, Huntington’s disease,
multiple sclerosis, tumor, epilepsy, or psychiatric diseases like schizophrenia
5) Consumption of greater than five alcoholic drinks per week within the last 30 days
6) Participants’ whose past medical history is pertinent for Chronic Obstructive Pulmonary
Disease, active infection, cancer, autoimmune diseases, or serious systemic illnesses, such as
hepatic, renal, or heart failure
7) Participants with visual, auditory, or other physical impairments that would interfere with
completing the study’s procedures and interventions:
a) Participants who are physically unable to partake in the interventions mindful meditation
and Dual N-Back
b) Participants who have relative or absolute contraindications for undergoing magnetic
resonance imaging (MRI), which includes claustrophobia and metal pieces implanted
inside the body
8) Education less than 9 years
3.7 Screening Procedure
1) The subject should meet the criteria for VCI, according to the VASCOG criteria.2 These
include:
a) Subjectively: Participants should state that they now require greater effort to complete
multiple tasks and feel fatigued and/or struggle with word finding and memory retrieval,
and/or bladder control. Presence of vascular risk factors will also support a diagnosis of
VCI.
b) Objectively:
i)

Physical Exam: Participants must present with at least one of the following clinical
features suggestive of CSVD: gait apraxia, urinary urgency, affective dysregulation
that includes apathy, or pseudobulbar affect.3
ii) Imaging at Magnetic Resonance Research Center (MRRC): Participants’ MRI imaging
must be positive for lacunar-strategic infarcts. Lacunar infarcts will be identified in
accordance with the Standards for Reporting Vascular Changes on Neuroimaging
(STRIVE)4 and Fisher criteria.5 Lacunar infarcts will be visually inspected on T1-, T2FLAIR, and T2-weighted images (WI) on MRI scans.5 To be classified as a lacunar
infarct, the lesion must be approximately 3-15 mm in diameter and accepted locations
are angular gyrus, thalamus, basal forebrain, basal ganglia, anterior cingulate, genu of
45

corpus callosum, fornix, lentiform nucleus, internal capsule, centrum semiovale, and
brainstem.6,4 Lacunar infarcts will be identified as round or ovoid-shaped rims of
increased signal relative to white matter on T2WI and T2-FLAIR images or decreased
attenuation on T1WI.5 Accepted lesion severity will be a Fazekas score of ≥2.7 Images
must be absent for cortical and watershed infarcts, hemorrhages, hydrocephalus, and
white matter lesions caused by non-vascular causes.3 Participants’ must have a
Scheltens atrophy score of zero in the hippocampus and entorhinal cortex.1
2) A MOCA score of less than 23 and more than 19 will be used to recruit participants. 8 They
should lose at least one point on Letter fluency (F, A and S)9 or vigilance A10.
3) Participants’ surrogates must confirm his or her MCI by completing the Informant
Questionnaire for Cognitive Decline in the Elderly.3 With a threshold score of 65, the test has
a sensitivity of 66.1% and specificity of 59.8%.11
4) Participants must screen negative for depression: Participants must score less than 16 on the
Centre for Epidemiologic Studies-Depression Scale (CES-D).12 The test has a specificity of
90%, sensitivity of 86%, and a positive predictive value of 80 with a cut-off score of 16.12
5) Participants must screen negative for anxiety, which will be measured by the Beck Anxiety
Inventory (BAI) test. A score less than nine will be accepted because it indicates “mild
anxiety.”13 BAI is a strong, valid, and reliable test in psychiatric populations, but it may not
always be able to discriminate between somatic factors and true anxiety.13 However, the BAI
is superior to the STAI in discriminating between somatic anxiety and trait anxiety and
separating patients with a current anxiety disorder from patients without the disorder.14
Please refer to the appendix to view baseline characteristics of participants.

3.8 Baseline and follow-up testing

Baseline testing will include tests not performed during the screening. Both baseline and
screening tests will be repeated during the follow-up. The tests will be scored and normed
according to age and education of the subjects.15 The tests include Category fluency (Animal,
Fruit, Vegetable)16, Digit span16, Digit symbol (DSST)3,16,17, Trails A and Trails B16, Boston
Naming Test (BNT)3,18, Neuropsychiatric Inventory (NPI)3,19, Letter fluency (F, A and S)9, Rey
Auditory Verbal Learning Test20 (RAVLT), Logical memory21, and Functional Activities
Questionnaire (FAQ).22 Please see the appendix section for more information on these tests. The
BNT, RAVLT, Logical memory, and Vigilance A test instruction and scoring manuals are not
included because they will need to be purchased.
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3.9 Randomization and Blinding

Once patients have passed screening, they will be assigned to placebo or intervention arms by
a pseudorandom number generator. The investigators will be blinded to the intervention and
placebo arms. The subjects will be told that we are comparing two different types of nonpharmacological interventions.

3.10 Interventions
3.11 Control Group: Low-Intensity Intervention
Participants who are randomized and allocated to the low-intensity intervention are offered tuition
for playing solitaire and listening to selected music for a total of one-hour per day. Participants
will be expected to play 30 minutes of solitaire followed by 30 minutes of listening to relaxation
music for 12 weeks. These activities will be placed on a server onto which they will need to log
onto to have their compliance recorded. They will be paid 5 dollars per session completed. For
those with less than 80% compliance on a weekly basis, one warning will be given, followed by
dys-enrollment from the study if low compliance continues.

3.12 High-Intensity Intervention
Participants enrolled in the combined mindfulness meditation (MM) and Dual N-Back will
come to clinic 3 times a week to play 30 minutes of Dual N-Back, followed by 30 minutes of
meditation. Participants will be expected to follow this same protocol on days that they are
not at clinic. These activities will be placed on a server onto which they will need to log onto to
have their compliance recorded. For those with less than 80% compliance on a weekly basis, one
warning will be given, followed by dys-enrollment from the study if low compliance continues.
Groups session will be mandatory during the first two weeks of the study, but after that, the
subjects may do the exercises at home if they wish.
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3.13 Cognitive Training
Participants will play the computerized adaptive training program, Dual N-Back, on
their devices. The Dual N-Back is adaptive as to ensure adequate intensity of training in these
individuals. The objective is to increase the length of time, or number of n-trials, one can
correctly recall information from. Participants will be presented every three-seconds with two
series of stimuli, single letters and images.23 Participants will need to determine if the presented
number and image location match what was presented to him or her two trials ago. Participants
will respond by pressing or not pressing a designated letter on a keyboard.
The game changes in level of task-difficulty based on performance. As performance
improves, the number of trials participants must recall stimuli from will increase. If performance
worsens, the number of trials will either decrease or stay at two. At the beginning of the study, all
participants will start with having to remember stimuli from two trials ago, but the training adapts
to participants’ own cognitive abilities and is personalized across participants. Participants’
results will be automatically uploaded into a computer to be analyzed later by an outcome
assessor. We will keep track of n-trials for each participant.
For participants to be included into data analysis, they must complete 80% of the total
Dual N-Back sessions. Adherence is measured by attendance and total number of uploaded
results. We will record the number of trails completed and task-difficulty level for each
participant.

3.14 Mindfulness Meditation
Participants will need to practice MM every day for thirty-minutes either at clinic or at
home. Group sessions will be offered three times per week. On days participants are not at
clinic, they will need to log onto a server at the beginning and end of each MM session to clock in
and out of the activity.
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Class sessions will include breath-awareness, body-scan, and gentle Hatha yoga. Breath
awareness exercises will ask participants to be cognizant of their breathing and to expand their
awareness onto other body sensations, thoughts, and emotions.24 Participants will then be asked to
nonjudgmentally accept those sensations and return their mental focus onto their breath. 24 Body
scans will ask participants to scan their body’s from head-to-toe to explore for different types of
sensations, such as pressure or tightness, and then to intentionally release that focus before shifting
onto the next body part.24 Hatha yoga exercises will require participants to gently stretch and slowly
move through different poses while focusing on present experiences.24
For participants to be included into the data analysis, they must complete 80% of the total
sessions. Adherence is measured by attendance and total number of logged in sessions on the
server.

3.15 Imaging Protocol
We will measure alterations in white matter microstructure by using Diffusion Tensor
Imaging (DTI), so called structural connectivity, and we will measure functional connectivity by
using c-fMRI. The c-fMRI images will be obtained while positive-tasks are being performed
by participants in the scanner. The positive task will be a succession of the Category Fluency—
Animals, Category Fluency- Vegetables, WAIS-R Digit Symbol, Digit Span Backwards, Trails A,
and Trail B tests. For each participant, connectivity matrices will be made during each of these
subtasks and averaged over the entire scan periods. Yale MRRC already standardizes the nodes
and regions of interest, and we will use these in our study. The aggregate subject connectivity
matrices are then used to look at correlations between connection strengths and test scores. This
can also be referred to as an edge and only significant edges will be kept (p<0.01). This analysis
can be run for both high-performance and low-performance. We will then examine if the sum of
the connection strengths in the high-performance network can predict ADNI-EF parameters. We
will also examine the sum off the connection strengths in the low-performance network to
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determine if it improves our model’s prediction power. We will repeat these steps for each of the
tests that composite the ADNI-EF. The same analysis will be performed using DTI, however it is
difficult to think of a mechanism whereby structural connectivity changes in a short period in
response to training. Please see the appendix section.
We will then see if changes in ADNI-EF, after cognitive training, are reflected in
connection strength in the high-performance network. If so, this would provide one of the most
convincing evidence for neuroplastic changes in response to cognitive training in the experimental
literature.
3.16 Study Variables and Measures
The composite ADNI-EF scores will be calculated for each intervention group in the same
manner it was computed in the study, “A composite score for executive functioning, validated in
Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive
impairment.”16 Once composite ADNI-EF scores are computed, we will then calculate a z score
for each intervention group by using the below equation. The Z score will be standardized to the
baseline mean and SD, with higher scores suggesting better performance.
Z= raw score – mean of the sample / standard deviation (SD) of the sample.
We will use these standard scores to compute our own prediction interval calculations. Interval
calculations will be computed by using the following standardized, mathematical equation.
P (Lower end-point of the mean population – z-score*SD) - mean population / SD < Z
score < (Upper-end point of the mean population – z-score*SD) – mean population / SD =
probability
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3.17 Statistical Analysis
3.18 Primary Outcome
To determine a significant difference between groups (group × time interaction) at the
end of the study, we will run an ANOVA Repeated Measures, Between Factors. Significance
will be set to p < 0.05. Analysis will follow per protocol. The independent variables are the
interventions, Low - intensity versus High - intensity interventions, and the dependent variable is
ADNI-EF z-score. The confounding variables that will be controlled for are for BAI scores, age
and sex.16

3.19 Secondary Outcomes
Modifications in cerebral blood flow and structural connectivity. To assess whether
both groups experienced significant changes in cerebral perfusion and structural connectivity
over 12 weeks, we will run a Two-Way Mixed-Model ANOVA (within-subjects’ factor: time;
between subjects’ factor: treatment). Significance will be set to p < 0.05. If significance is
found, we will run a post hoc test.
Effects on cognitive domains. To test the interventions’ effect on different cognitive
areas, we will calculate mean change in scores from baseline to twelve weeks post-treatment
initiation within-groups. To determine significance between groups, we will run a repeated
measures ANOVA.

3.20 Missing Data
Continuation in the study requires more than 80 % compliance with the
interventions. As with problems with missing data on neuropsychological testing, if the
constituents of ADNI-EF are missing from the data, the subject will be excluded from the
analysis. Proc MI will be used to determine the distribution of missing values.1
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3.21 Ethical Parameters
3.22 Subject Protection and Confidentiality
The study design will be carried out in accordance with the guidelines set by Yale’s
Human Investigation Committee (HIC) and Institutional Review Board (IRB) by adhering to their
regulations written in Procedures 100 PR1. 25 Our study will also follow the guidelines written
in Policy 340: Participation of Individuals with Impaired Consent Capacity.26 Participants must
have capacity to enroll into the study and also designate a study partner for collateral information.
Participants will need to sign the consent forms during the visit for eligibility screening. Lastly,
our protocol will include adequate provisions for monitoring collected data and ensuring privacy
and confidentiality so that our study is HIPPA compliant. Consent forms and study protocol will
be submitted to the Yale New Haven Research Unit Committee so that we may receive documented
approval and begin our study.
Experimental studies may involve potential and unforeseeable risks that include physical
harm or loss of confidentially. To mitigate potential harm, we have created a list of potential risks
and corresponding action plans to address them should they occur. This list will be provided to
participants in the consent form. Please refer to the consent forms in the addendum. Below, we
included our minimal risk data safety monitoring plan.

3.23 Minimal Risk Data and Safety Monitoring Plan
The Principal Investigator (PI) will be responsible for monitoring and protecting the data
under the laws of HIPPA, assuring that those involved in the study are adhering to the study
protocol that is provided to the IRB, and conducting, at minimum, monthly safety reviews. During
these review processes, the PI will assess whether the study’s protocol should continue unchanged,
require amendments, or close to enrollment. Changes in protocol will only be made in the interests
to protect participants’ safety. Before these changes are made, we will inform both participants
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and the IRB. The PI and the IRB will have the authority to stop or suspend the study or require
modifications.
Subjects’ overall risk for adverse events in this study are low, as exemplified by the
potential risks and associated action plans provided in the participants’ consent forms.
Interventions and methods will only be carried out by certified professionals who have completed
the training module, “Ethics on Human Research.” Medical tests and imaging will be conducted
by licensed staff members from the hospital; diagnoses will be made by certified neurologists;
outcome data will be collected and analyzed by experienced research assistants; meditation will be
taught by a certified instructor; neuropsychological tests will be evaluated by a psychiatrist or
neurologist.; and, the principal investigator, Dr. Salardini, is an appropriately trained medical
professional who has been trained in neuropsychiatry, neurology, and internal medicine.
In terms of risks unrelated to health, there is low-risk associated with collection and
attainment of subjects’ protected health information. We will be requesting for a signed consent
waiver during the recruitment process because this research could not be conducted without access
to and use of the protected health information. However, we ensure that the collected protected
health information will not involve increased risk to patient’s privacy; adequate plans will prevent
against the improper use and disclosure of identifying information; and, the identifying information
will be shredded and destroyed at the earliest opportunity, unless such retention is required by law
in the interests of patient safety. Lawful authorities will include members overseeing the research,
such as the IRB.
To protect confidentiality, methods to protect data will include the use of password
protected programs, encrypted software, use of secured servers, along with storing papers in
locked-filing cabinets. We will also separate personal identifying information and results, and
results will be published as group data to avoid using identifying information. Our study will
adhere to these provisions to avoid the potential harm that could occur should confidentiality be
unlawfully breached about one’s psychiatric and substance use history, serious illness, or the
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harmful consequences that can occur in the setting of a stolen identity. In the event of illegal
disclosure, the event will be documented in the “accounting for disclosures log,” and then
forwarded to the Deputy HIPAA Privacy Officer. Participants will be subsequently made aware of
the disclosure.
Additional safety measures will be included in this study because elderly with MCI
impairments are a vulnerable population. Security measurements will require participants to
identify a study partner who will be willing to provide additional help with participant participation
and accompany participants to each drop-off session and to all procedures. Participants must have
capacity to enroll in this study, which will be assessed by a medical provider. We will submit a
protocol application to the IRB, along with our signatures attesting to the protection of health
information, and the required HIPPA Authorization forms that participants must sign to participate
in the study.

3.24 Monetary compensation
Subjects will receive $5 per session and can receive a total compensation of $420 upon
completing the 84 sessions. They will receive a further $100 for completing both baseline and
follow-up testing, which includes MRIs and neuropsychological testing. These are nominal fees
and not coercive, they merely introduce a form of token economy to increase compliance.
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Chapter 4 – Conclusion
4.1 Rationale
4.2 Choice of condition to treat
a) As we discussed in detail within the introduction, the brain has different kinds and degrees
of neuroplasticity depending on the localization and age of subjects. The best examples of
neuroplasticity which appear to be present lifelong, or at least into old age, seem to pertain
to the frontal-subcortical circuitry which connect the frontal lobes with the basal ganglia,
and through the basal ganglia’s connections to the thalamus, to the rest of the brain. The
executive and cognitive control role of the frontal-subcortical circuitry means that
dysfunction in these areas have a disproportionate effect on overall cognitive functioning.
b) Additionally, we argued that evidence shows that the frontal-subcortical circuitry is
particularly vulnerable to the effect of CSVD.
c) It follows from a and b that a mechanism that might engage neuroplasticity may have the
opportunity to treat some of the executive dysfunction seen in CSVD.
4.3 The choice of intervention
a) We also reviewed how Dual N-Back has some of the best track records suggesting
effects on neuroplasticity of the brain. Some of our choices regarding this modality
included:
a. Using a single modality to reach enough intensity and repetition to cause plastic
changes, as well as avoiding interference.
b. We use a relatively high dose of intervention, which is at the limits of compliance
from our clinical experience for the same purpose.
c. The period of intervention is 12 weeks after which there is enough repetitions in
the task for it to become habitual.
b) We reviewed the effects of mindfulness meditation and how it suppresses the countercorrelated networks. There is a possibility that this may augment the effects of Dual
N-Back.
4.4 Hypotheses
1) Our primary hypothesis is that the high-intensive intervention in the form of Dual NBack training and mindfulness meditation will have a differential effect on executive
functioning in subjects with CSVD.
2) Exploratory hypothesis 1: We hypothesize that improved executive function will
positively affect other cognitive domains.
3) Exploratory hypothesis 2: Changes in executive function may be correlated with
changes in the connectivity in the cortico-subcortical circuitry.
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4.5 Specific Aims:
1) To demonstrate less negative change in ADNI-EF score during follow-up compared to
baseline, in the high-intensive intervention group compared to non-intensive
intervention group.
a) Subjects in the high-intensive intervention group will receive instructions to
play Dual N-Back daily (30-minutes) and to meditate (30-minutes) for 12
weeks, during which they have an option of performing this task in supervised
groups three times per week.
b) Subjects in the non-intensive arm will also receive instructions to play solitaire
daily (30-minutes) and to listen to calming music (30-minutes) for 12 weeks.
c) Nominal cash reward is given to increase compliance. A compliance of more
than 80% is required.
d) We will form the ADNI-EF composite score at baseline and after follow-up
for comparison.
2) To demonstrate that non-executive cognitive domains may be improved by a
strengthened executive functioning network:
a) We will perform neuropsychological testing and look at other domains namely
visuospatial, language and memory to see if there are improvements.
b) In our analysis, we will gauge what proportion is directly related to executive
function improvements.
3) To demonstrate changes in connectivity in response to cognitive training, we will
correlate c-fMRI with ADNI-EF
a) C-fMRI task positive imaging are constituents of ADNI-EF performance.
b) A composite weighted high-performance network is formed as per CPM
protocol.
c) Show that there is increased strength of connectivity in the high-performance
network.
d) Show that changes in f-MRI correlate with changes in ADNI-EF scores.
4.6 Expected outcomes
1) We expect the ADNI-EF in the intensive intervention to change in the positive direction in
the period of the study. The non-intensive group may show minor changes. The
expectation of positive change comes from the relatively short period of the study, during
which deterioration due to natural history is likely to be minimal.
2) We expect increases in the connectivity measures in the high-performance network.

4.7 Pitfalls
1) Non-pharmacological interventions are only incompletely standardized.
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2) We have not previously determined the maximum tolerated dose of intervention. However,
from the literature and our clinical experience, it is somewhere between 1 and 2 hours.
3) We have not performed a dose-response study. Given that interference is not a major issue
in this single-task training, at worst, the highest tolerated dose may be partially redundant
but is unlikely to have a negative effect. With unlimited funds and time, both 2 and 3
would have been proposed.
4) The diagnostic criteria for CSVD are as not optimal and can often include other subcortical
cognitive impairments in the cohort.
5) CPM is a new and hitherto unproven technology.
6) We make high demands on our subjects and compliance may become an issue.
4.8 Innovation
1) To our knowledge, our study will be the first to investigate in a cohort of MCI-CSVD the
impact of combined meditation and Dual N-Back on executive functioning, provide
biomarkers which may correspond to this change, and thus offer insight into executive
function’s relationship to connectivity.
2) We use a rigorously validated but underused measure, the ADNI-EF, which was developed
by looking at the ADNI database. The composite score allows us to use one endpoint as
to minimize multiple comparisons and makes the experiment more rigorous.
3) We use a highly innovative imaging biomarker, and if useful, it will open new possibilities
for clinical trials in this area.
4.9 Clinical and/or Public Health Significance
CSVD form of vascular cognitive impairment represents one of the major causes of
morbidity in our ever-aging population. Presently there are no interventions which have been
proven to improve cognition in this population. Demonstration of benefits, however small given
the number of people afflicted by this condition, will be greatly beneficial to public health.
Additionally, the technique we are auditioning in this study include ADNI-EF and CPM
have wider applications in other studies of cognitive training and rehabilitation and may lend
greater rigors to future experiments.
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Appendix I
Sample Calculation

Figure 1. Sample size calculation. G*Power 3.1.9.2 software was used to calculate our sample
size. We ran ANOVA Repeated measures, between factors. A priori power analysis computed
that 74 participants would be needed to determine a significant difference between two groups
with the study set at a 5% significance level, powered at 80%, and effect size-f set to 0.25. The
ADNI-EF test has not yet been studied in our sample population so we choose a medium effect
size, Cohen f 0.25.1 Please see the above figure to view the input parameters we set. The output
parameters were given to us by G*Power.
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Appendix II
Table 1. Baseline characteristics of subjects who were randomized to the study.
Combined MMP
and Dual N-Back
(n=37)

Control Group
(n=37)

Demographics Variables
Female (%)
Male (%)
Age (years)
(mean+ SD)
Education (years)
(mean+ SD)
Clinical Variables
Time Diagnosed with MCI
Before Start of Study (weeks)
(Mean + SD)
Risk Factors for Developing
Subcortical Dementia
HTN (%)
Type I DM (%)
Type II DM (%)
Average Hemoglobin A1C
(Mean + SD)
Obesity (%)
Hyperlipidemia (%)
Physically Inactive (%)
Smoking (Packs-per- Year)
(Mean + SD)
Drinks Per Week (Mean +
SD)
APOE ε4 Alleles: Average
Present
(Mean + SD)
Number of VaD Biomarkers
Present:
(Mean + SD)
Severity of VCI
Number of Clinical
Symptoms Suggestive of
CSVD
(Mean + SD)
Number of Cognitive
Domains Impaired
(Mean + SD)
Neuropsychological and
Behavioral Tests
MOCA
(Mean + SD)
Letter fluency (F, A and S)
(Mean + SD)
Vigilance A
(Mean + SD)
Informant Questionnaire for
Cognitive Decline in the
Elderly
(Mean + SD)
Neuropsychiatric Symptom:
Centre for Epidemiologic
Studies-Depression Scale
(CES-D)
(Mean +/- SD)
Beck Anxiety Inventory
(Mean +/- SD)
Proof of Vascular Disease
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P-Value

X2

Brain Parenchymal Fraction
Volume
(Mean +/- SD)
Lacuna Volume
(Mean +/- SD)
White Mater
Hyperintensities, Average
Fazekas Score
(Mean +/- SD)
Other Factors
Number of Medications
Prescribed Within the Past
Month that Affect Cognition
(Mean +/- SD)
Number of Medications
Prescribed Within the Past
Month that Affect Mood
(Mean +/- SD)

The Shapiro-Wilk test will be used to confirm that the random sample is normally distributed
for each of the outcome variables studied. Student t-test will be used to confirm that mean
variables are not significantly different between groups. Chi-square test will be used to
confirm that dichotomous variables are not significantly different between groups. Wilcoxon
rank-sum will be used to confirm that ordinal variables are not significantly different between
groups. Factors that affect the primary outcome, ADNI-EF, will be controlled for by multiple
linear regression analysis, which include age, education, gender, and any APOE-ε4 alleles.
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Appendix III
Table 2. Neuropsychological and behavioral tests used in this study.
Study /
Test

No. of
Healthy
Participants

Age and +/Years of
Education
of Healthy
Participants
(years)

Normative Scores
of Healthy
Participants and/or
Test Score Cut-off
Values

Test Validity

Nasreddine, Z: 2
MOCA

N= 90

Age =
72.84±7.03;
Education =
13.33±3.40

Cut-off score =
23.7±4.1

Letter fluency
(F, A and S) 3,4

N= 1343

Age = 53.63
(19.65) 3;
Education =
13.94 (2.01)

Mean score = 40.48

To detect MCI: Sensitivity =
90%, Specificity = 87%,
Test-retest reliability=
correlation coefficient=0.92,
P<.001, Internal consistency
Cronbach alpha = 0.83
Interrater reliabilities
(Pearson correlation
coefficients): r(42) = .95, and
switching, r(42) = .96.4

3

3

Vigilance A

5

Informant
Questionnaire
for Cognitive
Decline in the
Elderly6
Centre for
Epidemiologic
StudiesDepression
Scale (CES-D) 7
Beck Anxiety
Inventory8,9

Category
fluency:
Animals +
Vegetables10
Digit span10

N = 50

Age = 79.9
± 7.8

Cut off-score > 27,
significantly
impaired vigilant (or
sustained) attention

Mild
dementia =
107

Age =
70.10 ± 9.22,

Discrimination
between mildmoderate dementia:
cut-off score of 65

N =80 poststroke
patients

N = 71
Adults with
Anxiety
disorders

N = 229

N = 229

Education =
6.21 ± 1.70
Age > 65

Age = 34
y/o, Mean
duration of
anxiety
symptoms =
11.8 years
Age =
76.0±5.0;
Education =
16.0±2.9
Age
=76.0±5.0;
Education =
16.0±2.9

Cut-off score of 16

Sensitivity = 75.0 (65.7–
82.8); Specificity = 73.1
(72.4–90.1); Positive
Predictive Value = 85.3
(76.5–91.7); Negative
Predictive Value = 71.0
(60.6–79.9)
AUC of 0.666 (95%
confidence interval (CI),
0.601–0.732),
sensitivity = 66.1%,
specificity = 59.8%
Specificity = 90%, sensitivity
= 86%, and a positive
predictive value = 80

Mild anxiety < 9
points

Internal consistency
Cronbach’s alpha = 0.90 to
0.94, retest reliability ranges
between 0.62 - 0.93

Average Score =
34.6±8.1

p-valuec = <.001

Average Score =

p-valuec = <.001

7.4±2.2
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Digit symbol10

N = 229

Trails A10

N = 229

Trails B10

N = 229

Boston Naming
Test11

Healthy
Participants
(N)= 307

Neuropsychiatric
Inventory13

N = 40,
MMSE
scores mean
of 28.4
(healthy
elderly)
N= 27 male
veterans
with
dementia
MCI
participants
(n) = 5883

Rey Auditory
Verbal Learning
Test14
Logical
memory15

Age =
76.0±5.0;
Education =
16.0±2.9
Age =
76.0±5.0;
Education =
16.0±2.9
Age =
76.0±5.0;
Education =
16.0±2.9
Age = 77.2
(4.47);
Education =
13.5 (3.46)
Age >65

Age =
67.37 (7.64)
Education =
10.48 (3.28)

Healthy
participants
(n) = 10,741

Average Score =
45.7±10.2

p-valuec = <.001

Average Score =
36.4±13.2

p-valuec = <.001

Average Score =
89.2±44.3

p-valuec = <.001

Average score =
12.0 (SD+/-2.46)

Relatively reliable when
readjusted for age and
education12

Mean depression
score = 0.25, mean
disinhibition score =
0.13, mean
irritability score =
0.05
Dementia group =
25.36

Test-retest scores = 0.79 for
frequency (p = 0.0001) and
0.86 for severity (p = 0.0001)

From the ADNI 2:
LM-II educationbased cutoffs:

AUC area under the receiver
operating characteristic curve
Early MCI in ADNI
16+ years of education: 0.72
8-15 years of education: 0.70

16 years of
education: normal
≥9; early MCI = 9–
11; AD ≤8

P< 0.01, when age and
education are adjusted (F
(2,113) = 15.56, Pc .001)

8–15 years of
education: normal
≥5; early MCI = 5–
9; AD ≤4

Functional
Activities
Questionnaire16

N = 1108
MCI
participants

Age = 75.8
(8.9)
Education =
15.0 (3.2)

0–7 years of
education: normal
≥3; early MCI = 3–
6; AD ≤2
Differentiating AD
from MCI, cut-off
point of 5/6

ROC analysis = area under
the curve of 0.903, sensitivity
= 80.3%, specificity = 87.0%,
classification accuracy =
84.7%

We reported normative values from cognitively healthy, elderly participants because a memory
deficit is usually defined as 1 to 1.5 SD below the normative value when matched in age and
education level.17
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Appendix IV
Connectome Predictor Model

(A)

(B)

Figure 2. The steps into making an Executive Function Network Linear Model.
A) BOLD signal will be measured from each participant as they complete the ADNI-EF test and will be computed into a program as a
functional connectivity matrix. Image was taken from “Relating Brain Circuits to Behavior: David Van Essen at TEDxCaltech.”18
B) BOLD average signal time will be calculated in each voxel, or node. The strength of connection between nodes represents the matrix.
We will input each subject’s connectivity matrix and ADNI-EF scores into our executive functioning connectivity predictor model. With
the aggregated data, we can then compute a robust regression to show the association between ADNI-EF z-scores and the connectivity
matrix (p<0.01). By applying significance testing, edge strengths in the positive tail will be summed together to produce the predictive
positive network strength, and the edge strengths in the negative tail will be summed together to produce the predictive nega tive
network strength. Positive and negative network strengths can predict ADNI-EF z-scores by applying the “leave-one-out cross
validation method.”19 The linear network strengths that significantly correlate (p<0.01) functional connectivity to ADNI -EF z-scores
can then be used to predict ADNI-EF z-scores in new subjects. Image was taken from “Using connectome-based predictive modeling
to predict individual behavior from brain connectivity.” 20
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Appendix V
ADNI-EF Calculation

Figure 3. How to calculate composite ADNI-EF scores for each intervention group.
The first step is to calculate “Original EF Scores” for each participant. To calculate “Original EF
Score,” each of the six tests will need to be graded per its instructed protocol. Each test’s final
score is assigned a numerical categorical value, which is listed above on the first line. Original EF
score will be calculated by adding the categorical values from the six tests and then dividing by six.
After we determine each participant’s “Original EF score,” we will then calculate composite ADNIEF score for the two intervention groups. For each intervention, we will add the “Original EF”
scores and then divide by total number of participants in that intervention group. The above figure
came from the study “A composite score for executive functioning, validated in Alzheimer’s
Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment.”10
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Appendix VI
Table 3. Summary on review of the literature
Study

B QuintanaHernández
DJ21

Age and
Cognitive
Status
65-86,
Mild-severe
dementia

Conditions Compared

MMP-Donepezil (n=42);
Cognitive- Donepezil
(n=38); PMR- Donepezil
(n=45); Donepezil-Only
(n=43).

Duration

288 sessions total,
each session
90 minutes

Variables Controlled For

Measures of Outcome

Main Findings

Education, age, APOE
biomarker, HTN, diabetes,
dyslipidemia, psychiatric
diseases, antidepressants,
and anxiolytics.

Primary outcome: delay cognitive
decline as measured by MMSE
and CAMCOG scores,
significance determined by
Repeated-measures ANOVA (p <
0.05) and Cohen’s d

MMP-Donepezil was the only
intervention whose Cohen effect
sized on MMSE (Cohen D= 1.45)
and CAMCOG (Cohen D= 1.73)
scores remained steady throughout
the two-year study in the mildmoderate dementia group. These
scores declined significantly at 18
months in the Cognitive
Stimulation-Donepezil group and
at 6 months in the Donepezil-only
and PMR-Donepezil groups. These
interventions had no significant
effects in moderate-severe
dementia.
Participants in combined group
experienced significant most
improvements in Dual N-Back
performance (t(14) = 4.98, p <
0.001 (p<0.05) and decreases in
STAI trait worry scores (t(14) =
5.35, p < 0.001); and, this was the
only intervention group were a
significant correlation was
observed between attention and
STAI trait worry scores (r = −0.36,
N = 30, p = 0.05) and an almost
significant correlation between
trait worry scores and improved
performance (p=0.07)

CAMCOG measures spatial
memory, language, memory,
perception, attention, and praxia

Course-Choi 22

Control: M =
27; N-back: M
= 28; MMP: M
= 31;
Combined: M
= 29
Healthy adults

MMP-Dual N-Back (n=15);
sham-control group nonadaptive 1-back task (n=15);
MMP (n=15); Dual N-Back
group(n=15)

Total of 5 hours
across 7 days; postfollow up seven day
after the study
completed

MMP: Free Mindfulness
Project Audio

Dual N-Back: 24
practice trials and
160 experimental
trials
MMP: 23-minute
audio clip
Sham-group: 24
practice trials and
160 experimental
trials

Sham-group: Non-adaptive
1-back task

Willis, S. 23

Memory: M=
74 y/o; Speed:
M= 73 y/o;
Reasoning: M=
74 y/o;

Speed-processing (n = 702):
visual search and divided
attention;
Memory Training (n = 703):
teaching mnemonic
strategies; Reasoning

Majority of
participants: 10
sessions,
approximately 75
minutes long at
beginning of study

Baseline differences in
anxiety scores, age, and
gender

Outcomes: Attention (measured
by anti-saccade task);
performance (mean difference in
Dual N-Back performance
between groups over 7 days); and,
worrisome behavior (measured by
STAI trait worry scores)
Significance determined by mixed
ANOVA’s (Group x Time)
(p<0.05)

Sex, education, age,
MMSE score, health
status, and Short-Form-36Physical Function score.
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Outcomes: Memory (measured by
Hopkins Verbal Learning Test,
Rey Auditory-Verbal Learning
Test, and the Rivermead
Behavioral Paragraph Recall test);
Reasoning (measured by letter

Memory (effect size, 0.23 [99% CI,
0.11-0.35), speed-processing (0.76
[99% CI, 0.62-0.90), and
reasoning training (effect size, 0.26
[99% CI, 0.17-0.35]) significantly
improved participants test scores

Control: M= 74
y/o
MMSE >23

training (n = 699):
remembering and finding
patterns over trials; and,
Control Group- no contact
(n = 698)

series, letter sets, and word
series); Speed of processing
(measured by 3 field of view
subscales); and,
Functional outcomes: IADL
difficulty (measured by the
Minimum Data Set–Home Care).

Sub-group of
participants: 10
sessions in addition
to four, 75 minutes
sessions at 11 and
35 months
Outcomes were
collected yearly for
five years

Salminen, T. 24

Dual N-Back:
M= 65.0 y/o;
Control: M=
65.0 y/o
MMSE >28
Dual N-Back
young adults:
M= 24;
Control-Group
young adults:
M=24

Zhang, Y.
25

MMSE >27

Control group- no contact
(n= 21);
Dual N-Back (n= 26)

14 sessions, 50
minutes in duration

Exploratory analyses:
Dual N-Back young adults
(n=20)
Control-Group young adults
(n=18)

T2DM (n=20); Control
group (n=19); f-MRI data
obtained during resting state
and digital 1-back WM task

One-day: 1
instructional trial,
11 practice trials,
and 12 test trials

Cognitive differences
(assessed by MMSE >28
and MehrfachwahlWortschatz-Intelligenz
test>110), years of
education, years in
occupation, age, and
gender

Clinical variables (HbA1c,
lipid panel, and HTN),
cognitive status (MMSE),
performance with Dual NBack, symptoms of anxiety
and depression (SelfRating Anxiety Scale and
Self-Rating Depressive
Scale), Short-term memory
performance, age, gender,
and education.
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Modified intention-to-treat
protocol, significance calculated
by repeated-measures, mixedeffects model, and Bonferroni
(p<0.01)
Outcomes: Executive functioning
(defined by reaction times and
error rates in attentional blink,
task-switching, and WM updating
tasks)
Intention-to-treat protocol, threeway mixed-ANOVA (Betweensubject factors: Group; Withinsubject factors: Session (pretest
vs. posttest)) and Cohen’s d (p <
.01)

Outcomes: Differences in
working memory systems’
activity levels, as measured by βestimates, between groups during
the 1-back task and AVLT test.
Significance was determined by
two-sample t-tests and Cohen’s d.
Differences in functional
connectivity in working memory
systems between groups were
compared, as assessed by voxelwise one-sample t-test and
Cohen’s d (p< 0.05)

within that cognitive domain. The
effect sizes remained over five
years compared to the control
group-no contact.

Dual N-Back significantly
improved the three executive
functioning task scores in
comparison to the control group
(p<0.01).
The game’s plasticity was assessed
by comparing post-test
performance scores in the elderly
who received Dual N-Back with the
younger adult’s pre-test scores who
received Dual N-Back: no
significant difference between the
two groups was found (p>0.05),
despite significant differences
between their pre-test scores (M =
1.64 and M = 2.34, respectively), [t
(43) = −7.24, p < .001, Cohen’s d
= 2.14).
Significantly lower BOLD signals
during the 1-back task was
observed in T2DM patients’ in the
bilateral lingual gyri, the left
ventral lateral prefrontal cortex,
the inferior parietal lobule, and in
the right fronto-parietal network’s
connection with the lingual gyri
(P < 0.05, AlphaSim correction).
However, these areas became
significantly more activated when
completing the short memory tasks
in comparison to euglycemic
patients. The fronto-parietal
network’s increase in amplitude of
activity was significantly correlated
with improved AVLT short-term
memory scores (p<0.05).

Salminen, T. 26

Hölzel, B.
27

Dual N-Back:
M= 24 y/o;
Active control
group/ singleback: M= 24;
Control-No
contact: M= 25

MBSR: M= 39;
Control: M =
36;
Healthy: M=
36,
demographicall
y matched
individuals

Dual N-Back (n=20); Active
control group/ single-back
(n=18); and, Control-No
contact (n=18)

MBSR (N=15); Control
group-stress management
education (n=14)

16 sessions, thirtyminutes in duration:
in each session,
Dual N-Back and
single n-Back
participants
received 20 practice
trials and 12 test
trials

Age and sex

MBSR (N=15):
Once a week, 2hour sessions for
eight-weeks;
weekly homework
assignments that
take about 1000
minutes to
complete; and, one
eight-hour retreat
day

Age, gender, education
level, comorbid anxiety
diseases, SSRI’s, handdominance

Outcomes: Changes in white
matter density, as measured by
fractional anisotropy and mean
diffusivity; correlation between
changes in white matter and Dual
N-Back performance
Intention-to-treat protocol, group
× time effects (p<0.05)

Control group-stress
management
education (n=14):
Once a week, 2hour class session;
weekly homework
assignments that
take about 1000
minutes to
complete; and, one
eight-hour retreat
day

Outcomes: Reduced anxiety
(measured by decreases in prepost Beck Anxiety Inventory and
Perceived Stress Scale scores);
mean change in BOLD signal;
correlation between anxiety
scores and areas in the brain that
underwent significant changes in
activity levels; and, differences in
brain activity between GAD
participants and healthy
participants.
Intention-to-treat protocol,
ANOVA group-by-time
interaction (p<0.05)

Significantly higher mean changes
in fractional anisotropy values
were observed in the Dual N-Back
group when compared to both
single-Back group and passive
control group (p<0.05).
Significant increases in FA were
observed in the superior and
inferior longitudinal fasciculi, the
inferior fronto-occipital fasciculus,
the forceps minor, and the
corticospinal tract. The increases
in FA were not significantly
correlated with mean improved
changed in Dual N-Back scores (p
> .57). The study also did not find
significant differences in mean
diffusivity values.
MMP significantly reduced BAI
and PSS scores in comparison to
the control group (ANOVA: group
x time, p<0.05). MMP caused
significant mean increases in
BOLD signal in the right pars
opercularis, left pars triangularis,
and right rostral middle frontal
cortex in comparison to the control
group. These activated areas were
significantly correlated with mean
changes in BAI scores, but not PSS
scores. The BAI scores were also
significantly correlated to the right
amygdala strengthening its
functional connectivity with the left
rostral middle frontal cortex (ρ = −
.648, p < .001), the right rostral
middle frontal cortex (ρ = − .487, p
= .018), and the right superior
frontal cortex (ρ = − .424, p =
.044) (ANOVA group-by-time
interaction and Spearman's ρ
(0.05).
Differences in brain activity
between GAD participants and
healthy participants was assessed
by comparing combined GAD
imaging data to newly enrolled
healthy participants’. Healthy
participants were matched in
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Wetherell, J. 28

MMP: M= 70
y.o; Control:
M= 73 y.o
Subjective
cognitive
impairment

MMP (n= 47): Baseline
characteristics: WTAR score
= 37.7 (8.5); Memory
composite score = -0.07
(0.68); Verbal fluency = 0.205 (0.899); Stroop =
0.077 (0.954); Digit Span =
10.1 (2.7); Grooved = 105.1
(38.8); Peak cortisol
(ng/mL) = 5.2 (2.5);
PROMIS Anxiety = 20.8
(5.8); PSWQ = 28.4 (6.6)
Control Group (n= 56):
Baseline characteristics:
WTAR score= 40.6 (8.2);
Memory composite score = 0.23 (0.85); Verbal fluency
= -0.0900 (1.0); Stroop=
0.088 (1.149); Digit Span =
10.0 (2.8); Grooved = 105.0
(27.6); Peak cortisol
(ng/mL) = 4.9 (2.4);
PROMIS Anxiety = 19.9
(7.1); PSWQ = 27.7 (8.2)

Newberg, A.29

MMP- Kirtan
Kriya: M = 64
± 8 years old,

MMP- Kirtan Kriya (N=7):
Baseline characteristics:
Category Fluency-Animals
= 21.1 ± 7.9; Trails A = 30.5

MMP (n= 47): 8
weekly sessions, 90
minutes in duration.
Received
homework
assignments
Control Group (n=
56): Health classes
= 8 weekly
sessions, 90 minutes
in duration.
Received
homework
assignments

Age, clinical variables,
gender, education,
medications that can affect
mood and cognition,
cognitive differences at
baseline (assessed by the
PROMIS scale, Wechsler
Test of Adult Reading,
Digit Span subtest,
Grooved Pegboard Test,
Memory composite test,
and Cognitive control
composite test), prior
experiences with
mindfulness or yoga
practice or yoga, and
regular use of corticoid
steroids.

Primary outcomes: 1) Mean
change over time on memory and
cognitive control composite
scores between groups. Memory
composite scores were measured
by Immediate List, Immediate
story, Delayed list, and Delayed
Story. Cognitive control
composite scores were measured
by Verbal fluency, and Stroop:
Color-Word. 2) Mean change
over time between-groups on the
Digit Span and Grooved
Pegboard. Primary outcomes
were analyzed by covariance
models that controlled for
baseline score, condition, and
WTAR scores (p<0.05).
Secondary Outcomes: 1) Mean
change over time on anxiety and
depression scores, which were
assessed by PSWQ, PROMIS
Depression, and PROMIS
Anxiety. These outcomes were
analyzed by mixed effect models
(p<0.05). 2) Mean change in peak
cortisol levels between groups,
assessed by paired t-test (p<0.05)

8 week-long study
MMP-Kirtan Kriya
(n=7): 12 minutes
of Kirtan Kriya

Age, cognitive outcome
measures, MMSE scores
<16, and prior experience
with meditation or yoga

71

Intention-to-treat analysis
Outcomes: Mean changes in test
scores within-groups on Category
Fluency task, Wechsler Adult
Intelligence Scale, Digit Symbol

demographic variables. At
baseline, GAD participants’ right
amygdala activity was significantly
higher when viewing neutral faces
in comparison to healthy
participants’ (p = 0.0001). The
right amygdala, the right caudal
middle frontal (p = 0.009) and the
right lateral orbitofrontal cortex
areas (p = 0.0054) underwent
significantly lower pre-post BOLD
signals in comparison to healthy
participants’. These changes were
not significantly correlated to BAI
index scores.
MMP caused significant
improvements in memory
composite scores (p<0.046, effect
size = 0.28), PSWQ scores
(p<0.042, Effect size=-0.48), and
PROMIS Anxiety scores (p<0.061,
effect size = -0.42). A significant
correlation was found between
improvements in memory
composite scores and changes in
anxiety and depression scores (χ21
=4.5, P = .03). Significant
decreases in cortisol levels were
observed in the MMP group
(paired t = 3.8, P = .0015).
No significant differences were
observed in Digit Span scores
between groups (p<0.99, effect
size=-0.09)

Kirtan Kriya: Significant findings
between changes in CBF and test
score improvements were observed
on the following measures: right

MMSE = 28.1
± 0.7
Placebo-Music
group: M =
65.0 ± 9.,
MMSE = 29.0
± 1.0
MCI diagnosed
by NINCDSADRD

Chen, X. 30

Donepezil: M=
75 y/o, MMSE
= 29.8

± 12.2; Trails B= 105.5 ±
52; Digit Symbol = 63.7 ±
25.3; Logical Memory
Delayed = 10.6 ± 5.2; and,
POMS = 52.2 ± 12.9
Placebo-Music Group (n=7):
Baseline Characteristics:
Category Fluency-Animals
= 21.5 ± 5.0; Trails A = 37.0
± 11.7; Trails B= 132.5 ±
58; Digit Symbol = 67.6 ±
21; Logical Memory
Delayed = 12.3 ± 6.5; and,
POMS = 47.5 ± 17.2

daily; PlaceboMusic (n=7): 12
minutes of listening
to a neutral stimulus
daily

Donepezil (n=6); Placebo
(n=5)

Six months
Donepezil (n=6):
titrated to 10 mg
daily over six weeks
and then continued
10 mg daily dose
for six months

Placebo: M =
67 y/o,
MMSE= 29.6

Age, baseline cognitive
test scores, education, and
gender.

Substitution Test, Logical
Memory task, Trails A, and Trails
B (paired t-test, p < 0.05);
correlation between imaging and
neuropsychological test scores
(Pearson’s correlation, p<0.05);
and, mean changes in cerebral
blood flow within groups in
regions of interest (paired t-test, p
< 0.05). Regions of interest
included the inferior frontal,
superior frontal, superior parietal,
DLPFC sensorimotor, posterior
cingulate, orbitofrontal, anterior
cingulate, superior frontal
thalamus, superior parietal,
medial frontal, and amygdala
precuneus.
Outcomes: Mean changes in
cerebral blood flow during verbal
memory task and HVLT test, as
assessed by GE Signa 1.5T MR
scanner (independent-sample t
tests without correction, p<0.05)

Placebo (n=5)

Wilkinson, D.
31

Placebo: M =
74 y/o;
Donepezil
5mg: M= 75
y/o,
Donepezil
10mg: M= 76
y/o,

Placebo (n=193): Baseline
characteristics in scores:
Hachinski score= 9.6 ± 0.2;
ADAS-cog= 18.8 ± 0.7;
MMSE= 22.2 ± 0.3; CDRSB= 5.6 ± 0.2; ADFACS=
15.1 ± 0.7
Donepezil 5mg (n=208):
Baseline characteristics in
scores: Hachinski score =

Donepezil 5mg
(n=208): 5 mg
nightly for 24
weeks
Donepezil 10 mg
(215): 5 mg nightly
for 4 weeks
followed by 10
mg/nightly until
week 24
Placebo group= 193

Demographic
characteristics, clinical
variables, medications, and
neuropsychological tests
(Hachinski score, ADAScog, MMSE, CDR-SB, and
ADFACS)

Primary Outcomes: Mean change
from baseline scores on the
ADAS-cog and CIBIC-plus tests.
Secondary Outcomes: Mean
changes from baseline on MMSE,
CDR-SB, and ADFACS tests
Intent-to-treat (ITT) analysis
between groups (p<0.05); study
completion rate was 79.7%
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prefrontal cortex - Trails B task (R
= −0.61, p = 0.02); left thalamus Trails B task (R = −0.62, p =
0.02); and, left thalamus - Digit
Span Test (R = 0.56, p = 0.03)
No significant findings (changes in
CBF or neuropsychological test
scores or correlations) were
observed in the music group

Donepezil did not cause significant
changes in cerebral blood flow
during the HVLT test in
comparison to the place group
(p>0.05). Performance on the
HVLT remained stable in the
placebo group but increased in the
Donepezil group. However,
donepezil did cause a significantly
less decline in cerebral blood flow
during the verbal memory task in
comparison to the placebo group.
In the Donepezil group,
participants had a -1.32-mean
decline in the left temporal tissue
and a -1.44-mean decline in the left
frontal tissue in comparison to the
placebo group’s -3.13 mean
decline in the left frontal tissue and
-2.83 mean decline in the left
temporal tissue (p<0.05)
Significant mean changes in
improvement from baseline ADAScog scores were observed in the
Donepezil 5mg group ( −2.65 ±
0.48 at week) and Donepezil 10mg
group (−2.19 ± 0.44) but not the
placebo group (−0.10 ± 0.39) at
the end of the study (p<0.001).
Significant mean changes in
improvement from baseline MMSE
scores were also observed in both

MCI-VCI
confirmed by
NINDSAIREN

9.4 ± 0.2; ADAS-cog= 20.8
± 0.7; MMSE= 21.8 ± 0.3;
CDR-SB= 6.0 ± 0.2;
ADFACS= 15.7 ± 0.7
Donepezil 10mg (n=215):
Baseline characteristics in
scores: Hachinski score= 9.5
± 0.2; ADAS-cog= 20.6 ±
0.7; MMSE= 21.5 ± 0.3;
CDR-SB= 6.1 ± 0.2;
ADFACS= 16.1 ± 0.7

Ngandu, T 32

Multidomain:
M= 70 y/o;
MMSE= 26;
Control group:
M= 69;
MMSE=26

Multidomain group (n=
591): Baseline scores: NTB
Total score= –0·03 (0·55);
Executive functioning= –
0·03 (0·66); Processing
speed = –0·02 (0·78); and,
Memory = –0·03 (0·68)
Control group (n=599):
Baseline scores: NTB Total
score= 0·03 (0·59);
Executive functioning= 0·03
(0·69); Processing speed =
0·05 (0·84); and, Memory =
0·03 (0·66).

Donepezil groups at the end of the
study but not in the placebo group
(p<0.01). Significant mean
changes in improvement from
baseline CDR-SB scores was only
observed in the Donepezil 10mg at
the end of the study. No significant
improvements in ADFACS scores
were observed in the three groups
at the end of the study (p>0.05).
Donepezil appears to be safe in
participants because there were no
significant differences in adverse
events between the three groups.
Most common adverse events
included nausea, abnormal dreams,
insomnia, leg cramps, and rhinitis.

Reductions in doses
was not permitted
Outcomes collected
at weeks 12, 18, and
24

Multidomain group:
Diet (based on
Finnish Nutrition
Recommendations10 dietary eating
sessions); Physical
exercise (based on
Dose Responses to
Exercise Training
study protocol: 1-3
times per week
muscle strength
training and 2-5
times per week
aerobic exercise);
Computer-based
training: 72 sessions
(three times per
week, 10-15
minutes per
session). This was
conducted again 6
months later into
the study. Training
included executive
processes, working
memory, episodic
memory, and
mental speed.
Management of

Age, education, MMSE
scores, vascular and
lifestyle risk factors, and
cognitive differences (NTB
total score, executive
functioning, processing
speed, and memory).

Primary Outcomes: mean change
and estimated mean change in
NTB scores at 24 months between
groups (group × time interaction,
P<0.05)
Secondary outcomes: mean
change and estimated mean
change in executive functioning
scores, processing speed scores,
and memory scores between
groups at 24 months (between
group differences, p<0.05).
Executive functioning was
measured by: digit span, concept
shifting test (condition C), trail
making test (shifting score B –
A), and shortened Stroop tests.
Processing speed was measured
by: letter digit substitution test,
concept shifting test (condition
A), and Stroop test (condition 2).
Modified intention-to-treat to
account for missing data (p<0.05)
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The multidomain group’s estimated
mean change in NTB total z-score
at 2 years was 0.20 (SE 0.01, SD
0.51), and it was 0.16 (0.01, 0.51)
in the control group. The mean
difference in NTB total scores per
year between groups was 0.022
(95%CI 0.002–0.042, p=0.030).
Multidomain approach
significantly affected executive
functioning scores (p=0.039) and
processing speed scores (p=0.029).
The control group’s risk for decline
in NTB total score (odds ratio 1.31,
95% CI 1.01–1.71), executive
functioning, and processing speed
were significant in comparison to
the multidomain group (p<0.05).

metabolic and
vascular risk factors
(based on their
national evidencebased guidelines).
Control group:
health advice
classes given at start
of study and months
6, 12, and 24

Gibbons, L.10

Healthy: M=
76 y/o; MCI:
M= 75 y/o;
AD: M= 75 y/o

Healthy (n= 229): Baseline
characteristics: Education =
16 years; APOE allele =
27%; ADNI-EF score =
0.70±0.67; Category
Fluency Combined =
34.6±8.1; WAIS-R Digit
Symbol = 45.7±10.2; Digit
Span Backwards = 7.4±2.2;
Trails A = 36.4±13; Trails B
= 89.2±44.3; Clock Drawing
= 4.7±0.6; and, white matter
hyperintensities (cm3) =
0.68±2.34.

Outcomes collected
at baseline, and at 6,
12, and 24 months
Outcomes collected
at baseline and at
months 6, 12, 18,
24, and 36

Age, education, sex, and
the presence of one or
more APOE ε4 alleles

MCI (n= 390): Baseline
characteristics: Education =
16 years; APOE allele =
54%; ADNI-EF =
−0.03±0.77; Category
Fluency Combined =
26.7±7.3; WAIS-R Digit
Symbol = 36.9±11.2; Digit
Span Backwards = 6.2±2.0;
Trails A = 44.3±21.7; Trails
B = 131.0±73.5; Clock
Drawing = 4.7±0.6; and,
white matter
hyperintensities (cm3) =
0.60±1.09

Outcomes: Validate the utility of
ADNI-EF z-scores, defined as: 1)
find a significant correlation
between ADNI-EF scores and
detecting MCI-AD conversion; 2)
find a significant correlation
between baseline ADNI-EF zscores and MRI images from
selected brain regions:
Regression models, controlling
for age, education, sex, one or
more APOE alleles, and
intracranial volume, were used to
predict EF z-scores. White matter
hyperintensities were transformed
to log scale. Robust standard
errors were used (p<0.05). 3)
determine ADNI-EF scores ability
to detect change over time

Criteria for inclusion into data
analysis: all outcome measures
obtained from at least one visit

AD (n= 181)
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Results of Interest: ADNI-EF z
scores were significantly correlated
to MRI changes in the Caudal
Middle Frontal (2.29); Rostral
Middle Frontal (3.52); Superior
Middle Frontal (2.88); Lateral
Orbito-frontal (3.8); Medial
Orbito-Frontal = 2.34; and, ParsTriangularis (2.61); and,
significantly correlated with
changes in white matter hyperintensities (WMI) (−2.09)
(p<0.05). WAIS-R Digit Symbol
had the strongest correlation with
WMH (−2.31); Clock Drawing had
the strongest correlation with
thickness in the caudal middle
frontal regions (3.14); and, the
Trails had a strong correlation
with the rostral (3.73) and superior
middle frontal (3.14) regions and
with the pars-triangularis (3.03)
(p<0.05)

Sam 33

Age range: 50–
91 years old

75 participants, participants
enrolled were confirmed to
have moderate to severe
leukoaraiosis with no
cortical infarcts or white
mater lesions > 2cm and
Fazekas score > 2

Outcomes collected
at one session

Imaging spatial confounds

Outcome: cerebrovascular
reactivity (CVR)’s correlation
with white mater tissue integrity
Repeated-measures one-way
analysis of variance (ANOVA)
with dependent variable defined
as MRI parameters and
independent variable defined as
regions of interest.
Mauchly test and corrections were
made with Greenhouse-Geisser.
Significance set to percomparison p value
<0.05/3comparisons= 0.0167.
Bonferroni-corrected.

75

Negative CVR is significantly
correlated with decreased FA,
CBF, and cerebral blood volume

Appendix VII
Imaging Protocol
We will measure alterations in white matter microstructure by using DTI-DSC imaging,
and we will measure cerebral blood flow by using BOLD f-MRI. BOLD imaging data will
generate a map of long-distance connections between one area of grey matter to another and will
provide information on functional connectivity. DTI- DSC images will provide information on
structural connectivity. Informatics platforms are provided through the Human Connectome
Project, a project funded by the NIH. We will use 3T GE MRI scanners with an 8-channel phased
head coil to image participants.34 Prior to imaging, participants will be injected with a single dose
of imaging contrast, 0.1 mmol/kg of gadolinium, and will be asked to abstain from ingesting
caffeinated products eight hours before imaging. 34 We will follow the same imaging protocol
from a study that used DTI- DSC imaging, which is called “Cerebrovascular reactivity and white
matter integrity.” We will use the following eight image sequences from that study.34 Total
imaging time is about one-hour long for each participant.18

1) T1-weighted 3D spoiled gradient echo sequence: Slice thickness: 1.5 mm; no interslice gap;
matrix size: 256 × 256; field of view: 22 × 22 cm; flip angle: 8/20°; echo time (TE): 2.3/3 ms; and,
repetition time (TR): 7.8/9.5 ms
2) BOLD fMRI using a T2*-weighted echoplanar imaging gradient echo sequence: Slice thickness:
3.0/5.0 mm; field of view: 24 × 24 cm; matrix size: 64 × 64; flip angle: 85/90°; TE 30 ms; and, TR
2,000 ms
3) FLAIR images: Slice thickness: 3 mm; slices per volume: 36–52; no interslice gap; matrix size:
256 × 224/240 × 240; field of view: 22 × 22 cm; flip angle: 90°; TE 125/165 ms; TR 9,000/9,145
ms; and inversion time 2,200/2,800 ms
4) Diffusion tensor imaging with echoplanar imaging spin-echo sequence: Slice thickness: 3 mm;
matrix size: 76 × 62/128 × 128; field of view: 22 × 22 cm; b = 1,000 s/mm2; diffusion-encoding
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gradients: 23; non-diffusion-weighted B0 image: 2; TE 55/80 ms; and, TR 9,150/14,500 ms
5) Proton density/T2-weighted images using fast spin echo-XL sequence: Slice thickness: 3 mm;
matrix size: 128 × 128/256 × 209; field of view: 22 × 22 cm; flip angle: 90°; TE: 11.1/90 to 11/102
ms; TR: 2,500/7,200 ms
6) Multiecho T2 mapping using a fast spin echo-XL sequence: Slice thickness: 3 mm; no interslice
gap; matrix size: 256 × 192; field of view: 230 × 184/22 × 22 cm; TE: 13, 26, 39, 52, 65, 78, 91,
104, 117, 130, 143, 156 ms; and, TR: 5,000/6,000 ms
7) DSC perfusion scan using gradient-multiphase echo echoplanar imaging sequence: Slice
thickness: 5 mm; matrix size: 128 × 128; field of view: 27 × 27 cm; flip angle: 90°; TE: 31.5 ms;
TR: 1,725 ms; and, 50 slices per location
Image Reconstruction.
Each subject’s MRI data will be uploaded to image processing software for pre-processing
and data analysis. Images will be pre-processed for quality control, which will be assessed by the
same standards as in the ADNI-EF35 and Connectome Predictor Modeling studies.19 Image quality
will be evaluated quantitatively by boundary shift integral, voxel‐based morphometry, tensor‐based
morphometry, atlas‐based mapped volumetric, a measure of gray‐white matter contrast to noise,
and size of head motion movements.35 Images also will be evaluated qualitatively by having a
radiologist assess for the presence of artifacts, blurring/ghosting, flow artifact, intensity and
homogeneity, and gray‐white CSF contrast.35 Only images with mild to no-artifacts will be used.
Other images that will not be included in data analysis are: images from subjects with missing
ADNI-EF scores, one or more missing nodal data, and head artifacts greater than 0.06 mm. 19
DTI- DSC Images-Structural Connectivity. To quantify cerebral white matter dysfunction,
T2 image sequences will be used. T2 images will be measured with multi-echo fast spin-echo
sequence.34 T2 images will be pre-processed with a product called “FMRIB's Diffusion Toolbox
(FDT)” to improve quality image.34
To calculate fractional anisotropy and mean diffusivity, diffusion-weighted images will be
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imported into FSL software for pre-processing and measurement calculations.34 Cerebral blood
flow maps will come from the time-signal attenuation data obtained from the preprocessed
weighted images. The area of perfusion that will be assessed is from the middle cerebral artery.34
BOLD-Functional-Connectivity. Each subject’s MR-images will be pre-processed and
analyzed in AFNI and FSL softwares.36 Pre-processing will include slice timing correction,
motion correction through a general linear model, correcting signal-to-noise ratio, and
controlling for anatomical variability across subjects with the “Gaussian smoothing filter” set
at 6 mm.36 The imaging software will enable us to smooth out the cortex’s convoluted surfaces
and view portions of the brain in left and right hemisphere surfaces and volume slices to view
subcortical structures.18 The representation of the brain’s shape will remain preserved.18 We will
use left and right hemisphere surface maps combined with volume slices to visualize and analyze
functional MRI.18 BOLD data will be analyzed within our regions of interest in these right and left
hemisphere surfaces and in subcortical, cerebellar, and cortical ribbon f-MRI views.18
Combining Participant’s Images. We will aggregate participants’ BOLD and T2weighted images by pre-processing them in SPM8 software and FSL.36 To help align subject
data, myelin map data will be used because they have landmarks that help align cortical areas
between subjects.18 Myelin maps of activity will be generated by dividing the intensity value of
T1-Weighted images from the intensity value of T2-Weighted images.18 Red myelin indicates a
heavily, active myelinated region.18 The myelin map will then be compared to functional
connectivity maps to determine if these maps colocalize.18
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Beck Anxiety Inventory
Below is a list of common symptoms of anxiety. Please carefully read each item in the list.
Indicate how much you have been bothered by that symptom during the past month, including
today, by circling the number in the corresponding space in the column next to each
symptom.
Not at all

Mildly but it
didn’t bother
me much.
1
1
1
1
1

Moderately - it
Severely – it
wasn’t pleasant at bothered me a
times
lot
2
3
2
3
2
3
2
3
2
3

Numbness or tingling
Feeling hot
Wobbliness in legs
Unable to relax
Fear of worst
happening
Dizzy or lightheaded
Heart pounding/racing
Unsteady
Terrified or afraid
Nervous
Feeling of choking
Hands trembling
Shaky / unsteady
Fear of losing control
Difficulty in breathing

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

1
1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3
3

Fear of dying
Scared
Indigestion
Faint / lightheaded
Face flushed
Hot/cold sweats
Column Sum

0
0
0
0
0
0

1
1
1
1
1
1

2
2
2
2
2
2

3
3
3
3
3
3

Scoring - Sum each column. Then sum the column totals to achieve a grand score. Write
that score here ____________.

Interpretation
A grand sum between 0 – 21 indicates very low anxiety. That is usually a good thing. However,
it is possible that you might be unrealistic in either your assessment which would be denial or
that you have learned to “mask” the symptoms commonly associated with anxiety. Too little
“anxiety” could indicate that you are detached from yourself, others, or your environment.
A grand sum between 22 – 35 indicates moderate anxiety. Your body is trying to tell you
something. Look for patterns as to when and why you experience the symptoms described
above. For example, if it occurs prior to public speaking and your job requires a lot of
presentations, you may want to find ways to calm yourself before speaking or let others do
some of the presentations. You may have some conflict issues that need to be resolved.
Clearly, it is not “panic” time but you may want to find ways to manage the stress you feel.
A grand sum that exceeds 36 is a potential cause for concern. Again, look for patterns or times
when you tend to feel the symptoms you have circled. Persistent and high anxiety is not a sign
of personal weakness or failure. It is, however, something that needs to be proactively treated
or there could be significant impacts to you mentally and physically. You may want to consult
a counselor if the feelings persist.

Beck Anxiety Inventory® Aaron T. Beck. Publication Date: 1990, 1993

CATEGORY FLUENCY TEST
Adopted from Sager MD, MA. Screening for Dementia in Community-based Memory Clinics.
Instructions
The instructor will say the following:
“I’m going to give you a category and ask you to name all the different examples that you can
think of from that category in one minute. For instance, if I said flowers, you might say rose,
daisy, etc. Do you understand?”
“Now go ahead and tell me all the different ANIMALS you can think of.”
Procedure:
1) Time for 60 seconds and tape record all responses.
2) If the person stops before 60 seconds, say “Any more animals?”
3) If the person says nothing for 15 seconds, say “A dog is an animal. Can you tell me more
animals?”
4) Repeat the above instructions for the category vegetable.
Notes
1.
2.
3.
4.

Write down everything that the subject says, including comments
Note down the corresponding times at which the participant provides an answer
If participants ask questions during the test, instructors may provide brief answers
If subjects stop before the minute is over, encourage them to continue with the task.
If subjects continue to refuse, say “There are a few seconds left, so we’ll just let the
time run on.”

Sager MD, MA; Hermann PhD, BP; LaRue PhD, A; Woodard PhD, JL, Screening for
Dementia in Community-based Memory Clinics. Wisconsin Medical Journal 2006.105(7)2529

SCORING Category Fluency
Animal Naming

Scoring: Count the total number of animals but do not include repetitions or non-animal words.
Total score: __________
Vegetable Naming

Scoring: Count the total number of vegetables but do not include repetitions or non-vegetable
words.
Total score: __________
Note: A score less than 14 is abnormal.
Directions for Scoring Animal and Vegetable Naming Tasks
Individual credit can be given for general category terms, like dog and terriers. However, only
1 point can be given when people name the same animal or vegetable at different developmental
stages, such as sheep and lamb.
Sager MD, MA; Hermann PhD, BP; LaRue PhD, A; Woodard PhD, JL, Screening for
Dementia in Community-based Memory Clinics. Wisconsin Medical Journal 2006.105(7)2529

Center for Epidemiologic Studies Depression Scale (CES-D)©, NIMH
Below is a list of the ways you might have felt or behaved. Please tell me how often you have
felt this way during the past week.
During the Past Week
Rarely or none
of the time (less
than 1 day)

Some or a little
of the time (1-2
days)

Occasionally or a
moderate amount
of time (3-4 days)

Most or all of
the time (5-7
days)

SCORING: Zero points for answers in the first column, 1 point for answers in the second
column, 2 points for answers in the third column, and 3 points for answers in the fourth
column. The scoring of positive items is reversed. Possible range of scores is zero to 60, with
higher scores indicating the presence of more symptomatology.
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DIGIT SYMBOL SUBSTITUTION TEST
1. Background and rationale
The Digit Symbol Substitution Test (DSST) may be a more sensitive measure of dementia
than the MMSE. The DSST requires response speed, sustained attention, visual spatial skills
and set shifting. It is part of the Wechsler Adult Intelligence Scale, one of the most widely
used measures of intelligence. It has been associated with subsequent mortality,
independent of comorbidity in the CHS cohort.1
The DSST requires that the participant fill in a series of symbols correctly coded within 90
seconds. In this test, the higher the score, the better the person’s performance.
2. Equipment and supplies

•
•
•
•

No. 2 pencils with eraser
Stop watch
DSST task sheet
Scoring template for DSST

3. Safety issues and exclusions
None
4. Participant and exam room preparation
The DSST should be administered in a quiet place with minimal distractions at a desk or
table the participant can use to write on. Unless it is policy at the clinic for examiners to
never knock or open a closed examination room door, we strongly encourage that a special
sign be posted indicating that the DSST is being administered and to please not interrupt
the test. If any temporary condition that may detract the participant from their optimal
performance cannot be removed, the participant should be moved to another location; if
this is not possible, reschedule the exam.
Ask the participant if they are comfortable. Reassure them that this is a routine test of
concentration that will be done several times during the course of the study.
5. Detailed measurement procedures
5.1 General issues/description
This is a standard neuropsychologic test. The participant completes the task of recording
the symbols that correspond to a series of digits. The task is timed. This is a pencil and
paper task. The participant practices on a sample, copying the correct symbol given for
each number. The participant then is timed on the actual task. The score is the number
correct in 90 seconds.

DSST.OM
Version 1.0
5/26/05
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•

It is imperative to review the instructions very deliberately and to speak slowly, and
for those participants who are hard of hearing, speak low, not loudly.

•

Be certain that participants understand the instructions before proceeding with the
test.

•

Be certain that participants who wear reading glasses are wearing them.

•

Read the standardized script exactly as it is written.

•

Do not offer encouraging words or in any way distract the participant, unless they
actually stop and need to be encouraged to continue.

5.2. Preparation for test: Determine if participant wears glasses for reading.
Script: “Do you usually wear glasses to read?”
If the answer is yes, ask the participant to put on their glasses.
Script: “Please put on your glasses.”
5.3 Instructions

1) Place the task sheet before the participant and point to the task.
Script: “Look at these boxes across the top of the page. On the top of each box
is a number from one through nine. On the bottom part of each box, there is a
symbol. Each symbol is paired with a number.”
Point to the four rows of boxes.
Script: “Down here are boxes with numbers on the top, but the bottom part is
blank. What I want you to do is to put the correct symbol in each box like this.”
Fill in the first three sample boxes.
Script: “Now I want you to fill in all boxes up to this line.”
Point to the line separating the samples from the test proper.

2) Let the participant attempt the sample.
•
•
•

If the participant has difficulty completing the ten sample items or does not
understand the task, help them complete the sample items.
If the participant still has difficulty or does not understand the task,
discontinue the task, and indicate on the form that the participant was unable
to complete the sample.
Give participants with physical limitations (e.g., arthritis or visual
limitations) an opportunity to complete the sample.

DSST.OM
Version 1.0
5/26/05
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If a visually or physically impaired participant cannot complete the sample,
check “unable to test” on the form or do not record scores.

3) After the demonstration and practice is complete, point to the first box following
the sample items and say:
Script: “When I tell you to begin, start here and fill in the boxes in these four
rows. Do them in order and don’t skip any. Please try to work as quickly as
possible. Let’s begin.”
4) If the participant stops filling in the boxes before the 90 seconds have passed,
give them standard encouragement.
Script: “Can you go further?”
5) If the participant begins to erase filled boxes, tell the participant not to waste time
erasing.
6) Stop the participant after 90 seconds. (Note: do not tell them what the time limit
is)
Script: “That’s good. That completes this set of tasks.”
5.4 Scoring

1) Indicate whether or not the participant completed the sample.
•

If they were not able to complete the sample (not due to a physical
limitation, such as poor vision), check off “unable to complete sample,”
record “00” for “number completed,” and mark “00” for “number incorrect.”

•

If they refused to complete the sample, check off “refused” and do not
attempt to score the test.

•

If they are unable to complete the sample due to a physical limitation, such
as poor vision, do not attempt to score the test.

2) If they completed the sample, check “sample completed” and go on to the timed test.
3) When it is known that a participant is dyslexic and will therefore draw some types of
symbols backward, those symbols which are drawn exactly backward are scored as
being correct.

4) Single blank spaces between two completed items are not considered incorrectly
coded symbols.

5) Two or more blanks which occur consecutively signal the end of the task. Symbols
coded after two or more blanks are not included in totals recorded.

DSST.OM
Version 1.0
5/26/05
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6) Enter the number completed.
7) Enter the number of symbols incorrectly coded.
8) One blank space does not count as completed or as incorrect.
9) Additional Scoring Notes
•

An “A” is not acceptable for the carat “^” sign (symbol for number 7).

•

A “U” with a tail is acceptable for the “U” symbol (symbol for number 5).

•

A flat-bottomed “U” is also acceptable for the round-bottomed “U” (symbol
for
number 5).

6. Alert values/follow-up/reporting
When testing is completed, thank the participant without offering specific feedback on their
performance.
7. Quality assurance
7.1 Training requirements
The examiner requires no special qualifications or prior experience for performing this
assessment. Training should include:
• Read and study manual
• Attend training session on techniques (or observe administration by experienced
examiner)
• Practice on volunteers
• Discuss problems and questions with local expert or QC officer
7.2 Certification requirements
• Complete training requirements
• Conducts exam on two participants while being observed by QC officer
• Correctly scores sample forms
7.3 Quality assurance checklist
Exam performed in quiet, private area without interruptions
Participant asked if they wear reading glasses
Explanation of test:
Instructions are given clearly, concisely and slowly
Participant was asked if they understand testing procedure
Test demonstration and practice:
Script read exactly as written (no omission, deletions or
substitutions) - Subtle changes allowed only if instructions need
to be repeated.

DSST.OM
Version 1.0
5/26/05
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Demonstrated in first 3 sample boxes
Participant completes 10 sample items - proper aid is given if
participant has difficult completing items.
Proper coding of answers for difficulty in completing or visual
impairment
Test administration:
Script read exactly as written
Participant instructed to begin and asked to stop after 90 seconds
Scores are coded properly (# completed, # incorrect); symbols not
counted after two blanks.
Reviews form for completeness
Correctly completes form
8. Reference
1. Fried LP, Kronmal RA, Newman AB, et al: Risk factors for 5-year mortality in older
adults: the Cardiovascular Health Study. JAMA 1998 Feb 25;279(8): 585-592.
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10. Data collection form
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THE DIGIT MEMORY TEST
Adopted from Martin Turner
Digits forwards
Start

Item A

Finish

Failure on both trials of a pair.

Directions

“Listen carefully as I say some numbers. When I finish, you say them.”

Delivery

Digits should be given at the rate of one per second. Administer both
trials of each item. Recite digits in an even monotone without any
variation in pitch of voice.

Scoring

The individual’s score is the total number of items correctly repeated
forwards.

WORKED EXAMPLE

In this example, the total correct is 5.
Digits Backwards
Directions

Instructor will say, “Repeat these numbers after me, but this time, I want you
to say the digits backwards.” Give two practice trials of two digits first – any
two numbers. If the subject gets them wrong, correct her or him. If the
subject repeats the digits forwards, give a reminder that they should be
reversed.

Score

Same as for digits forwards.

Final score

Sum total correct for backwards and forwards. Consult Standard Score table,
which is listed below. This can also be expressed as a percentile equivalent,
please refer to Percentile Equivalent table which is also listed below.

Comparison

Most people can remember two more digits forwards than they can
backwards. If the gap is larger than three, or smaller than one, this may be
worthy of note.

Page 1

DIGITS FORWARDS
Item

First trial

√ or X

√ or X

Second trial

A

43

16

B

792

847

C

5941

7253

D

93872

75396

E

152649

216748

F

3745261

4925316

G

82973546

69174253

H

246937185

371625948

Total

Forwards score:
DIGITS BACKWARDS
Item

Trial one

Trial two

A
B
C
D
E
F
G

83
475
2619
28736
624719
4183627
52624197

29
615
3852
59413
276391
1586937
94617385

√ or X

Backwards score:
FINAL SCORE:
Total forwards and backwards:
Standard score:
Percentile equivalent:

Martin Turner
Jacky Ridsdale
revised 6th October 2004
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Total

Table 1. Estimated standard scores for digit memory performances from six years-old to
adulthood (Adopted from Martin Turner).
Age

6

7

8

9

10

11

12

13

14

15

16

Adult

Raw score
4

74

57

60

56

54

55

50

48

52

52

51

50

5

79

63

65

61

59

59

55

53

56

56

55

54

6

85

69

70

66

64

64

59

57

60

60

59

57

7

90

75

75

71

69

68

64

61

64

64

63

61

8

96

81

80

76

74

73

68

66

68

68

66

64

9

101

87

85

81

79

77

73

70

72

72

70

68

10

106

93

90

86

85

82

77

74

76

75

74

71

11

112

99

95

91

90

86

81

78

80

79

78

75

12

117

105

100

96

95

91

86

83

84

83

82

79

13

123

111

105

101

100

95

90

87

88

87

86

82

14

128

117

110

106

105

100

95

91

92

91

89

86

15

134

123

115

111

110

105

99

96

96

95

93

89

16

139

129

120

116

115

109

104

100

100

98

97

93

17

144

135

125

121

121

114

108

104

104

102

101

96

18

150

141

130

126

126

118

112

109

108

106

105

100

19

155

147

135

131

131

123

117

113

112

110

108

104

20

161

153

140

136

136

127

121

117

116

114

112

107

21

145

141

141

132

126

122

120

118

116

111

22

150

146

146

136

130

126

124

121

120

114

23

155

151

152

141

134

130

128

125

124

118

24

159

156

157

145

139

134

132

129

127

121

25

150

143

139

136

133

131

125

26

154

148

143

140

137

135

129

27

159

152

147

144

141

139

132

28

163

157

152

148

144

143

136

29

156

152

148

147

139

30

160

156

152

150

143

31

160

156

154

146

32

164

160

158

150

33

154

34

157

35

161

36

164
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Table 2. Standard scores expressed as a percentile equivalent. (Adopted from Martin
Turner).
Standard
score

Percentile
equivalent

Standard
score

Percentile
equivalent

54

0.1

77

6

100

50

123

94

55

0.1

78

7

101

53

124

95

56

0.2

79

8

102

55

125

95

57

0.2

80

9

103

58

126

96

58

0.3

81

10

104

61

127

96

59

0.3

82

12

105

63

128

97

60

0.4

83

13

106

66

129

97

61

0.5

84

14

107

68

130

98

62

0.6

85

16

108

70

131

98

63

0.7

86

18

109

73

132

98

64

0.8

87

19

110

75

133

99

65

1

88

21

111

77

134

99

66

1

89

23

112

79

135

99

67

1

90

25

113

81

136

99.2

68

2

91

27

114

82

137

99.3

69

2

92

30

115

84

138

99.4

70

2

93

32

116

86

139

99.5

71

3

94

34

117

87

140

99.6

72

3

95

37

118

88

141

99.7

73

4

96

39

119

90

142

99.7

74

4

97

42

120

91

143

99.8

75

5

98

45

121

92

144

99.8

76

5

99

47

122

93

145

99.9
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Standard
score

Percentile
equivalent

Standard
score

Percentile
equivalent
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with Dementia
By: Ann M. Mayo, DNSc, RN, FAAN
Hahn School of Nursing & Health Science, University of San Diego
WHY: Dementia is a neurodegenerative disease where functional ability in
individuals with dementia (IWD) declines over time. The majority of care costs in
IWD are directly attributed to functional disability (Hurd, 2013). Compromised
functional ability is unsafe for IWD, anxiety provoking for families and costly to
health care organizations. Valid and reliable clinical information about functional
ability can be used to individualize care and design safe and supportive
environments thereby promoting the highest level of independence for individuals
with dementia. Therefore, an effective and efficient method for measuring
functional ability is important.
BEST TOOL: The Functional Activities Questionnaire (FAQ) measures
instrumental activities of daily living (IADLs), such as preparing balanced meals
and managing personal finances. Since functional changes are noted earlier in the
dementia process with IADLs that require a higher cognitive ability compared to
basic activities of daily living (ADLs) (Hall, 2011; Peres et al., 2008), this tool is
useful to monitor these functional changes over time. The FAQ may be used to
differentiate those with mild cognitive impairment and mild Alzheimer’s disease. To
further exemplify the importance and utilization of the FAQ, thousands of research
participants across the United States are administered the FAQ annually as part of
the National Alzheimer’s Coordinating Center (NACC) longitudinal research study
taking place in 29 National Institute on Aging-funded Alzheimer’s Disease Centers
(Weintraub et al., 2009).
TARGET POPULATION: Older adults with normal cognition, mild cognitive
impairment, as well as mild, moderate, and advanced dementia (Weintraub et al.,
2009). The FAQ is appropriate for clinical settings, such as acute and primary care,
rehabilitation, assisted living, and home settings, as well as for research.
VALIDITY AND RELIABILITY: In IWD the FAQ is a consistently accurate
instrument with good sensitivity (85%) to identify an individual’s functional
impairment. The FAQ demonstrates high reliability (exceeding 0.90). Tests of
validity have been performed on the FAQ establishing it as an instrument for the
bedside and research because it can discriminate among different functional levels
of individuals, predict neurological exam ratings and mental status scores such as

the Folstein Mini-Mental Status Examination (MMSE) and demonstrate sensitivity
to change (Assis, 2014; Malek-Ahmadi, 2015; Pfeffer, 1982).
STRENGTHS AND LIMITATIONS: The FAQ is efficient to administer to older
adults giving consistent results across different professionals and settings including
primary care settings, as well as with different forms of dementia (Mayo, 2013;
Tabert et al., 2002). As with other instruments that measure functional activities
using indirect approaches, there may be over or under estimation of abilities because
of the lack of direct observations.
FOLLOW-UP: Continued monitoring of IADLs in IWD is important to ensure
environmental adaptations keeping these individuals safe. The measurement of
IADLs is also important for advancing science. Therefore, the FAQ is an important
measure for clinicians and researchers.
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Functional Activities Questionnaire

Administration
Ask informant to rate patient’s ability using the following scoring system:
• Dependent = 3
• Requires assistance = 2
• Has difficulty but completes task independently = 1
• Normal = 0
• Never did [the activity] but now can = 0
• Never did and would now have difficulty = 1
1.

Writing checks, paying bills, balancing checkbook

2.

Assembling tax records, business affairs, or papers

3.

Shopping alone for clothes, household necessities, or groceries

4.

Playing a game of skill, working on a hobby

5.
6.

Heating water, making a cup of coffee, turning off stove after
use
Preparing a balanced meal

7.

Keeping track of current events

8.

Paying attention to, understanding, discussing TV, book,
magazine
9. Remembering appointments, family occasions, holidays,
medications
10. Traveling out of neighborhood, driving, arranging to take
buses
TOTAL SCORE:
Evaluation
Sum scores (range 0-30). Cut-off point of 9 (dependent in 3 or more activities) is
recommended to indicate impaired function and possible cognitive impairment.

Pfeffer, R.I., Kurosaki, T.T., Harrah, C.H. Jr., Chance, J.M., & Filos, S. (1982). Measurement of
functional activities in older adults in the community. Journal of Gerontology, 37(3), 323-329.
Reprinted with permission of Oxford University Press.

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)©
Instructor will say the following:
“Now, we want you to remember what your friend or relative was like 10 years-ago and to compare
it with what he/she is like now today. 10 years-ago was in (write down the year). Below are
situations where this person has to use his/her memory or intelligence and we want you to indicate
whether this has improved, stayed the same, or got worse in that situation over the past 10 years.
Note the importance of comparing his/her present performance with 10 years ago. For example, if
10 years ago this person always forgot where he/she had left things, and he/she still does, then this
would be considered 'Hasn't changed much'. Please indicate the changes you have observed by
circling the appropriate answer.”
Compared with 10 years ago, how is this person at:

LETTER FLUENCY TEST
Instructions
Instructor will say the following:
“I’m going to give you a letter of the alphabet and ask you to name as many different words
as you can think of that start with that letter. I don’t want you to include names of people or
places. You’ll have one minute to think of as many different words as you can. Try not to
give the same words with different endings, like for example, run, runner and running.”
“Now go ahead and tell me all the different words that you can think of that start with the
letter F.”
Repeat the above instructions for the letters A and S.

SCORING LETTER FLUENCY
1) Scoring Tip: Consult a dictionary to see if the word given is a noun. As a rule of thumb, if
the word has a separate entry to a similar word, as for pill and pillbox, it is scored as a correct
response.
2) Sum the total number of correct responses.
3) Note the corresponding times the answers are provided
4) Compute reaction times by calculating the mean time interval between the first word
retrieved and subsequent words retrieved.

Patterson J. (2011) F-A-S Test. In: Kreutzer J.S., DeLuca J., Caplan B. (eds)
Encyclopedia of Clinical Neuropsychology. Springer, New York, NY

The Neuropsychiatric Inventory–Questionnaire:
Background and Administration

The Neuropsychiatric Inventory–Questionnaire (NPI-Q) was developed and cross-validated
with the standard NPI to provide a brief assessment of neuropsychiatric symptomatology in routine
clinical practice settings (Kaufer et al, J Neuropsychiatry Clin Neurosci 2000, 12:233-239). The
NPI-Q is adapted from the NPI (Cummings et al, Neurology 1994; 44:2308-2314), a validated
informant-based interview that assesses neuropsychiatric symptoms over the previous month. The
original NPI included 10 neuropsychiatric domains; two others, Nighttime Behavioral
Disturbances and Appetite/Eating Changes, have subsequently been added. Another recent
modification of the original NPI is the addition of a Caregiver Distress Scale for evaluating the
psychological impact of neuropsychiatric symptoms reported to be present (Kaufer et al, JAGS,
1998;46:210-215). The NPI-Q includes both of these additions.
The NPI-Q is designed to be a self-administered questionnaire completed by informants about
patients for whom they care. Each of the 12 NPI-Q domains contains a survey question that
reflects cardinal symptoms of that domain. Initial responses to each domain question are "Yes"
(present) or "No" (absent). If the response to the domain question is "No", the informant goes to
the next question. If "Yes", the informant then rates both the Severity of the symptoms present
within the last month on a 3-point scale and the associated impact of the symptom manifestations
on them (i.e. Caregiver Distress) using a 5-point scale. The NPI-Q provides symptom Severity and
Distress ratings for each symptom reported, and total Severity and Distress scores reflecting the
sum of individual domain scores.
Most informants will be able to complete the NPI-Q in 5 minutes or less. It is
recommended that responses to the NPI-Q be reviewed for completeness by a clinician and for
clarifying uncertainties after each administration. The first time an informant completes the NPIQ,
it may be useful to verbally review the instructions. In some instances, it may be necessary to
conduct the NPI-Q in part or entirely as an interview.
The NPI and NPI-Q are both copyright-protected by Jeffrey L. Cummings, MD. The NPI-Q was
developed by Daniel Kaufer, MD with permission. Use of the NPI or NPI-Q in investigational
studies sponsored in whole or part by for-profit entities is prohibited without express written
consent.
For inquiries regarding the NPI-Q, contact:
Jeffrey L. Cummings, MD
Mary S. Easton Center for Alzheimer's Disease Research
10911 Weyburn Ave; #200
Los Angeles, CA 90095
jcummings@mednet.ucla.edu
The NPI-Q can be found at:
www.NPItest.net

Please answer the following questions based on changes that have occurred since the
patient first began to experience memory problems.
Circle "Yes" only if the symptom(s) has been present in the last month. Otherwise,
circle "No". For each item marked "Yes":

a) Rate the SEVERITY of the symptom (how it affects the patient):
1 = Mild (noticeable, but not a significant change)
2 = Moderate (significant, but not a dramatic change)
3 = Severe (very marked or prominent, a dramatic change)

b) Rate the DISTRESS you experience due to that symptom (how it affects
you):
0
1
2
3
4
5

= Not distressing at all
= Minimal (slightly distressing, not a problem to cope with)
= Mild (not very distressing, generally easy to cope with)
= Moderate (fairly distressing, not always easy to cope with)
= Severe (very distressing, difficult to cope with)
= Extreme or Very Severe (extremely distressing, unable to cope with)

Please answer each question carefully. Ask for assistance if you have any questions.
Delusions

Yes

No

Hallucinations

Yes

No

Does the patient have false beliefs, such as thinking that others
are stealing from him/her or planning to harm him/her in some
way?
SEVERITY: 1 2 3

DISTRESS: 0 1 2 3 4

5

Does the patient have hallucinations such as false visions or
voices? Does he or she seem to hear or see things that are not
present?
SEVERITY: 1 2 3

DISTRESS: 0 1 2 3 4

5

Agitation/Aggression Is the patient resistive to help from others at times, or hard to
handle?
Yes

No

SEVERITY: 1 2 3

DISTRESS: 0 1 2 3 4

5

Depression/Dysphoria Does the patient seem sad or say that he /she is depressed?
Yes
Anxiety

No

SEVERITY: 1 2 3

DISTRESS: 0 1 2 3 4

Does the patient become upset when separated from you? Does
he/she have any other signs of nervousness, such as shortness of
breath, sighing, being unable to relax, or feeling excessively
tense?

5

Yes

No

Elation/Euphoria

Yes

No

Apathy/Indifference

Yes

No

Disinhibition

Yes

No

Irritability/Lability

Yes

No

Motor Disturbance

Yes

No

Nightime Behaviors

Yes

No

Appetite/Eating

Yes

No

SEVERITY: 1 2 3

DISTRESS: 0 1 2 3 4

5

Does the patient appear to feel too good or act excessively
happy?
SEVERITY: 1 2 3

DISTRESS: 0 1 2 3 4

5

Does the patient seem less interested in his/her usual activities or
in the activities and plans of others?
SEVERITY: 1 2 3

DISTRESS: 0 1 2 3 4

5

Does the patient seem to act impulsively, for example, talking to
strangers as if he/she knows them, or saying things that may hurt
people's feelings?
SEVERITY: 1 2 3

DISTRESS: 0 1 2 3 4

5

Is the patient impatient and cranky? Does he/she have difficulty
coping with delays or waiting for planned activities?
SEVERITY: 1 2 3

DISTRESS: 0 1 2 3 4

5

Does the patient engage in repetitive activities such as pacing
around the house, handling buttons, wrapping string, or doing
other things repeatedly?
SEVERITY: 1 2 3

DISTRESS: 0 1 2 3 4

5

Does the patient awaken you during the night, rise too early in
the morning, or take excessive naps during the day?

SEVERITY: 1 2 3

DISTRESS: 0 1 2 3 4

5

Has the patient lost or gained weight or had a change in the type
of food he/she likes?
SEVERITY: 1 2 3

DISTRESS: 0 1 2 3 4

5

NPI-Q SUMMARY
No

Severity

Caregiver Distress

Delusions

0

1

2

3

0

1

2

3

4

5

Hallucinations

0

1

2

3

0

1

2

3

4

5

Agitation/Aggression

0

1

2

3

0

1

2

3

4

5

Dysphoria/Depression

0

1

2

3

0

1

2

3

4

5

Anxiety

0

1

2

3

0

1

2

3

4

5

Euphoria/Elation

0

1

2

3

0

1

2

3

4

5

Apathy/Indifference

0

1

2

3

0

1

2

3

4

5

Disinhibition

0

1

2

3

0

1

2

3

4

5

Irritability/Lability

0

1

2

3

0

1

2

3

4

5

Aberrant Motor

0

1

2

3

0

1

2

3

4

5

Nighttime Behavior

0

1

2

3

0

1

2

3

4

5

Appetite/Eating

0

1

2

3

0

1

2

3

4

5

TOTAL
Developed by Daniel Kaufer, MD. Final Version 6/99. © JL Cummings, 1994; All rights
reserved.

Trail Making Test (TMT) / Trails “A” & “B”

This test of cognitive function has two parts: Trails “A” and “Trails B.” Trials A requires the
individual to connect a sequence of 25 numbers in order. Trails “B” requires the individual to
alternately connect a sequence of 25 numbers and letters (e.g. 1-A-2-B-3-C, etc.).
Trail Making Test (TMT) / Trails “A” & “B”
Link to Tool
Time to
Administer
Type

http://www.sagelink.ca/uploads/tools/TrailMakingTestAB.pdf
2 – 5 minutes

Setting

Primary care.

Administration

Trail Making Part A:
1. Provide the person with the sample Trails A first. Once completed correctly,
then move on to the actual Trails A.
2. Instruct the individual to “Please draw a line connecting the numbers 1, 2, 3, 4
etc. in order until you reach the end. Try to draw the lines as fast as you can.”
3. If the person makes a mistake on the sample Trails A, point it out to them and
explain the error. Repeat the sample Trails A until they have completed it
correctly or it becomes evident that they are unable to do the task.
4. Once the sample trails A has been completed correctly, give them the real Trails
A. Repeat the instructions as given in step two.
5. Start timing the test as soon as the instruction is given to begin the test.

Standardized Screening Tool

Trail Making Part B:
1. Provide the individual with the sample Trails B. Once they have completed it
correctly, then move on to the actual Trails B.
2. Instruct the individual that this second part of the test is slightly more difficult as
it requires them to alternate between numbers and letters. Instructor will say,
“On this page are some numbers and letters. Begin at 1 and draw a line from 1
to A, A to 2, 2 to B, and so forth until you reach the end. Remember first you
have a number, then a letter, then a number, and so on. Draw the lines as fast as
you can.”
3. If the person makes a mistake on the sample Trails B, point out the error and
explain why it is incorrect. Repeat this procedure until the task is performed
correctly or it becomes apparent that they cannot complete the task.
4. After the person has completed the sample Trails B, provide them with the actual
Trails B. Repeat the instruction given in step 2. Timing begins as soon as the
person is told to begin.
5. Be alert for mistakes. If the person makes a mistake, point it out to them
immediately, return the person to the last correct circle, and continue the test
from that point. Continue timing and record the number of errors made until
task is completed.

Interpretation

Reference

1. Part A and B are scored separately. The score for each part is the number of seconds
required to complete the task.
2. More than 1 error or a score below the 10th percentile in time (seconds) raises
concerns. Scores are compared against the 50th percentile.
3. Generally, time over 3 minutes or more than 1 error is a failure.

Corrigan J.D., Hinkeldey M.S. (1987). Relationships between parts A and B of the Trail
Making Test. JClin Psychol., 43(4), 402–409.
Gaudino E.A., Geisler M.W., Squires N.K. (1995). Construct validity in the Trail
Making Test: what makes Part B harder? J Clin Exp Neuropsychol., 17(4), 529-535.
Lezak M.D., Howieson D.B., Loring D.W. (2004). Neuropsychological Assessment.
4th ed. New York: Oxford University Press; 2004.
Reitan R.M. (1958). Validity of the Trail Making test as an indicator of organic brain
damage. Percept Mot Skills, 8, 271-276.

CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL:
Hospital Research Unit
Study Title: Brain Training and Meditation’s Effects on Memory in Seniors with Vascular
Cognitive Impairment
Principal Investigator: Dr. Salardini
Funding Source: None
Invitation to Participate and Description of Project
You are invited to participate in a research study designed to look at two safe, nonpharmacological interventions effects on slowing cognitive decline in Vascular Cognitive
Impairment.
You have been asked to participate because we are seeking participants between the ages
of 60- 89 who have mild cognitive impairment (MCI) due to cerebral small vascular disease
(CSVD), and we would like to provide you an intervention that may slow the progression of
certain cognitive declines that are common in this disease, like problem-solving capabilities. The
study will be conducted at Yale New Haven Hospital Research Unit.
In order to decide whether or not you wish to be a part of this research study, we want
you to carefully review its risks and benefits to make an informed decision. This consent form
includes the study’s purpose, its procedures and associated risks, possible benefits, and possible
alternative treatments. If you still wish to participate in the study after reviewing this document,
we ask that you sign this form.
Description of Procedures
If you agree to join this study, you will be asked to play a computer game and to engage in a
relaxing activity. A description of this clinical trial will be available on
http://www.ClinicalTrials.gov, as required by U.S. Law. The site may post a summary of our
results, but no participants will be able to be identified on this site.
Intervention- I
Participants enrolled in the combined mindfulness meditation (MM) and Dual N-Back
will come to clinic 3 times a week to play 30 minutes of Dual N-Back, followed by 30 minutes of
meditation.

Intervention- II
Participants who are randomized and allocated to the low-intensity intervention are
offered tuition for playing solitaire and listening to selected music for a total of one-hour per day.
Participants will be expected to play 30 minutes of solitaire followed by 30 minutes of listening to
relaxation music for 12 weeks.
Participants will be expected to follow this same protocol on days that they are not at
clinic. These activities will be placed on a server onto which they will need to log onto to have
their compliance recorded. For those with less than 80% compliance on a weekly basis, one
warning will be given, followed by dys-enrollment from the study if low compliance continues.
Groups session will be mandatory during the first two weeks of the study, but after that, the
subjects may do the exercises at home if they wish.
Risks and Inconveniences
Experimental studies may involve potential and unforeseeable risks that include physical harm or
loss of confidentially. To mitigate potential harm, we have created a list of potential risks and
corresponding action plans to address them should they occur.
Risks of Magnetic Resonance Imaging (MRI)
Magnetic resonance (MR) imaging is a technique that uses magnetism and radio waves to
take pictures and measure chemicals of different parts of the body. The United States Food and
Drug Administration (FDA) has set guidelines for magnet strength and exposure to radio waves,
and we will carefully observe those guidelines.
MRI is usually a harmless procedure; however, risks can occur. On rare occasions, some
people may feel uncomfortable or anxious due to claustrophobia or may develop dizziness, an
upset stomach, a metallic taste, tingling sensations, or muscle twitches. These sensations usually
go away quickly, but please inform the research staff if you have them.
People with metal objects both inside or physically on their bodies are at greatest risk for
harm because the MRI’s strong magnets will harm you. To minimize these risks, the exclusion
criteria includes people with pacemakers, metal pieces inside their body, aneurysm clips, large
colored tattoos, or any other contraindications for MRI, and people who are claustrophobic. To
lower the risk of harm from metal objects, each participant will be scanned by a metal detector
every time before entering the MRI room. No metal objects will be present in the MRI rooms and
doors will remained closed during sessions to prevent metal objects from the outside entering the
room. During the MRI study, participants will be provided earplugs and closely monitored.

Should a participant become anxious or experience any adverse event, the MRI study will be
discontinued and rescheduled for a later time, if it is not contraindicated.
We want participants to be aware of the risks and harms associated with MRI’s, so we
request that participants read and answer the questions on the MRI Safety Questionnaire.
Participants will be required to sign and hand-in the completed Questionnaire.
MRI results are for research purposes only. Only in the event of a concerning finding,
will the image be reviewed by a certified, practicing radiologist at our facility to provide a
diagnostic evaluation of the image. Based on the radiologist’s impression, the PI will inform the
subject of the finding and recommend that the participant seek his or her primary care provider
for further medical advice. We, the investigators, the Magnetic Resonance Research Center, and
Yale University are not responsible for further treatment.
Risks of Intravenous Catheter Placement and Gadolinium Contrast
Having an intravenous (IV) line placed is benign procedure. Though, standard risks
include mild pain, infection, bruising, or clot formation. To minimize these risks, registered
nurses will be performing these tasks and using proper technique. A total of 200 mL of blood will
be collected during the entire study. Should an adverse event occur, participants will receive
appropriate medical arrangements from a licensed health care health provider.
Gadolinium is an FDA approved contrast that is used in MRI imaging. This contrast is
safe in participants with good kidney function, and very rarely do people experience an adverse
reaction.
Gadolinium risks are greatest in people with kidney dysfunction because it could
potentially cause a life-threatening disease Nephrogenic Systemic Fibrosis/Nephrogenic
Fibrosing Dermopathy (NSF/NFD). To avoid this risk, participants who have a glomerular
filtration rate (eGFR) of <30 mL/min/1.73 m2, receive dialysis, or have acute kidney injury will
not be included in this study. Detailed information on the contrast agent Gadolinium can be
provided to you at your request.
Risks of Discontinuation of Pharmaceuticals
The inclusion criteria requests that participants not be on anti-anxiolytics or medications
that alter cognition six weeks prior to the start of the study. These medications include
tranquilizers, anti- anxiolytics, hypnotics, ionotropic, cholinomimetic agents, cholinesterase
inhibitors, or NMDA antagonists. These medications would confound outcome measurements in
our study. Participants who have relative contraindications in discontinuation of medications will
not be included.

The risks of discontinuing these drugs are unknown. We cannot predict the risk of
cognitive decline since there is no standard of care in mild-VCI treatment, only it is common
practice to prescribe medications that are used in AD. Cholinesterase inhibitors are an off-label
treatment because their benefits on cognitive outcomes or slowing disease progression is not
supported by empirical evidence.1
In the advent that participants unexpectedly present with worsening cognitive
impairments, he or she can choose to opt-out-of the study and receive donepezil or no treatment
at all. Participants are able to withdraw from the study at any time, and his or her relationship
with Yale Hospital will not be adversely affected.
Once the study is complete, the treatment with significantly better outcomes will be
available to participants.

Risks of Worsening Cognitive Impairment Symptoms
Participants will be monitored for progressive cognitive decline that could potentially by
exacerbated by our interventions or screening protocol. In the event that a participant experiences
an abrupt decline from baseline, the participant will be evaluated by a neurologist at our clinic
who is licensed to address changes in cognition and activities of daily living (ADL). These
patients will be seen within 48-hours of onset of symptoms and appropriate medical arrangements
will be made. We will track these participants until resolution. In the event that the decline is so
severe that the participant’s surrogate can no longer care for him or her, that participant will be
admitted to the hospital and appropriate medical interventions will be provided, in addition to
case management. We will track these participants until resolution. This risk is highly unlikely.

Risk of Fatigue
The intervention is one-hour in duration daily, which may cause participants to become
fatigued. To avoid this, participants will be provided breaks as needed. Other ways we can
mitigate fatigue is by splitting the sessions into smaller periods or provide longer rest breaks.

Risks of the Screening and Evaluation Process
The screening process requires us to ask personal psychiatric and medical history, which
may make participants feel uncomfortable. To mitigate this risk, the screening process will only
be conducted by trained and experienced research assistants who are able to conduct interviews in
a sensitive manner.

Risks of Inconvenience
The study should be relatively convenient for participants. Participants will only have to
engage in their assigned activity for a total of one hour each day. Coming to the research unit may
be inconvenient but participants are only required to come to the clinic three times per week for
the first two weeks and on days that outcome measurements are collected.
Benefits
The low risks associated with this study are outweighed by its potential benefits. The
current treatment options in CSVD are poor, as it is common practice to prescribe off-label, AD
medications.
The non-pharmacological interventions are harmless and some have shown to promote
plasticity and functional network strengthening that may be able to improve functional and
cognitive deficits. Participants will have the opportunity to help us learn more about these
interventions neuroplastic effects by agreeing to undergo functional magnetic resonance imaging.
The knowledge gained from our study could also lead to new treatment options in CSVD.
Economic Considerations
Participants will not be charged for any medical interventions that he or she receive in the
study. Participants will need to own a computer device to play the computer game. Also, subjects
will receive $5 per session and can receive a total compensation of $420 upon completing the 84
sessions. They will receive a further $100 for completing both baseline and follow-up testing,
which includes MRIs and neuropsychological testing. According to the rules of the Internal
Revenue Service (IRS), this payment may be considered taxable income.
Treatment Alternatives/Alternatives
The current guidelines from the American Academy of Neurology (AAN) in the
treatment of mild cognitive impairment suggest that “Grade A” practice is to discuss with patients
the option of cholinesterase inhibitors; however, clinicians must emphasize to patients that they
are an off-label treatment because their benefits on cognitive outcomes or slowing disease
progression is not supported by empirical evidence.1 “Grade B” practices are to not offer
cholinesterase inhibitors or to add twice-weekly exercises into overall management.1 A “Grade
C” practice is to recommended cognitive interventions because they may improve cognitive
functioning.1 Guidelines also suggest that it is good practice to assess and treat comorbid,
behavioral and neuropsychiatric symptoms because of their association with greater functional
impairments2 and increased risk for disease progression.3,4 Other primary interventions that are

being studied are aerobic exercise and lifestyle modifications, such as diet, exercise, and reducing
blood pressure.
In this study, participants will be asked to play a computer game and to engage in a
relaxing activity. In the advent that participants unexpectedly present with worsening cognitive
impairments, he or she can choose to opt-out-of the study and receive donepezil or no treatment
at all. Once the study is complete, the treatment with significantly better outcomes will be
available to participants.

Confidentiality
Members of the research team will be collecting protected health information, including
medical information and some HIPAA identifiers, throughout this study for the sole purpose of
research and medical charting. Upon participants signed consent, we will be able to access and
collect information about your personal health history, which includes current and past medical
history, medications, psychiatric and substance use history, family history, and diagnostic lab
results. During the screening process, the HIPAA identifiers that will be obtained include names,
telephone numbers, and medical record numbers. This information will remain confidential and
protected, but adverse effects could potentially occur should confidentiality be unlawfully
breached. In the event of illegal disclosure, the event will be documented in the “accounting for
disclosures log” and then forwarded to the Deputy HIPAA Privacy Officer. Participants will be
subsequently made aware of the disclosure.
To protect confidentiality, participants’ information and outcome measures will be
collected and handled only by trained personnel from the Hospital Research Unit and Magnetic
Resonance Imaging Center. Data will be recorded into Excel spreadsheets on a protected server.
Both excel documents and server will be password protected. Digital data will be stored onto
password protected databases. All electronic devices will have encrypted software and be on a
protected server. Papers with personal information will be stored in locked-filing cabinets. Only
researchers involved in this study will have access to passwords and filing cabinets and will have
successfully completed HIPPA training. We will access participant information only when
necessary.
To help protect confidentiality, personal identifying information and results will be
separated. Results will be published or presented in conferences as group data to avoid using
identifying information. Unnecessary data will be shredded or permanently deleted at the earliest
opportunity. Though, impactful data may be kept in a locked filing cabinet up to ten years but
will only be accessible to authorized personnel. Any identifiable information that is obtained in

connection with this study will remain confidential. Information will not be disclosed to any other
person or entity, unless with your permission or as required by law in the interests of patient
safety. We are legally required to disclose abuse and certain reportable diseases. Lawful
authorities include U.S. and State Law Officials and members overseeing the research, such as
the Institutional Review Board. Representatives from the Yale Human Research Protection
Program and the Yale Human Investigation Committee, a committee that reviews, approves, and
monitors research on human subjects, may inspect study records during internal auditing
procedures. These individuals are required to keep all information confidential.
Consent personnel includes I, Sarah Savoia, and PI, Dr. Salardini. Consent to screen for
eligibility and participation in the study will be obtained at the Church Street Research Unit.
We request that participants with capacity and assigned caretaker sign the HIPPA
Authorization form in order to participate in the study.

In Case of Injury
In the event that a participant is injured or experiences an abrupt decline from baseline,
the participant will be evaluated by a neurologist at our clinic, and we will pay and provide for
the appropriate medical arrangements. Injuries that are non-research related will not be
financially covered by Yale-New Haven Hospital.
However, in the event that a concerning finding is observed on MRI, we, the
investigators, the Magnetic Resonance Research Center, and Yale University will not be
responsible for further treatment. The participant will be recommended to seek his or her primary
care provider for further medical advice and treatment.

Voluntary Participation and Withdrawal
Participating in this study is voluntary, and participants are able to withdraw from the
study at any time. Refusal to participate or withdrawal from the study will not adversely affect
your relationship with Yale Hospital. We would still treat you with standard therapy or, at your
request.

Withdrawing from the Study
To withdraw from the study, you can call a member of the research team at any time. The
interventions will be discontinued and you will no longer be able to receive these interventions
from us outside of the study. The monetary compensation will be forfeited as well. Participants
will not be able to re-enroll into this study.

Participants may be withdrawn from the study in the event of disease progression,
development of serious side effects, or less than 80% adherent to protocol.
In the event a participant is no longer a part of the study, we will immediately stop
collecting outcome measurements and identifying information. Prior collected data may still be
used in our study.
Participants will be unable to withdraw their data because we will be anonymizing it and
separating results from personal identifying information.
You do not give up any of your legal rights by signing this form.
Questions
If you have any remaining questions about this study, please ask us before signing.
Authorization
I consent to voluntarily participate in this study after having read this document. I attest that I
have full capacity and understand the study’s general purposes, my involvement, and the possible
hazards and inconveniences, as they were clearly explained to me. My signature also attests to
having received a copy of this consent form.
Participant
Name of Participant:
Signature:
I assign,

, to be my caretaker.

Caretaker
As the assigned caretaker, I voluntarily consent to let the above participant participate in this
study after having read this document. I understand the study’s general purposes, my
involvement, and the possible hazards and inconveniences, as they were clearly explained to me.
For the foreseeable future, I agree to accompany the above participant to all drop-off sessions and
procedures.
Name of Designated Caretaker:
Signature:
Relationship:
Date:

For the Researcher

Signature of Principal Investigator
If you have further questions about this project or if you have a research-related problem,
you may contact the Principal Investigator Dr. Salardini at (203) 785-4085.
If after you have signed this form and you have any questions about your privacy rights,
please contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with someone
other than the researchers to discuss problems, concerns, and questions you may have concerning
this research or to discuss your rights as a research subject, you may contact the Yale Human
Investigation Committee at (203) 785-4688.
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